Introduction {#s1}
============

Tuberculosis killed approximately 1.6 million people in 2017, with around 10 million new active cases ([@bib80]). The continued difficulty in treatment arises, in large part, from long and relatively complex treatment regimens, currently requiring at least 6 months of treatment with multiple antibiotics ([@bib80]). Failures in treatment and poor patient adherence have driven the emergence of drug-resistant strains that present further therapeutic and public health challenges. Host-directed therapies (HDTs) are a new conceptual approach designed to enhance host-mediated clearance of bacteria or limit immunopathology rather than targeting bacterial processes directly ([@bib9]; [@bib28]). By targeting host processes, HDTs present an orthogonal approach to existing antibiotics. Notably, they avoid the danger of commonly arising bacterial mutations that eliminate binding of the drug to a bacterial target. Although a number of potential HDTs for tuberculosis (TB) have been identified in cell-culture-based models and directed animal studies, few have advanced to clinical trials ([@bib9]; [@bib28]).

The complex lifestyle of *Mtb* renders it particularly amenable to host-directed therapies at multiple points in its lifecycle, providing a number of druggable host targets ([@bib67]; [@bib68]). Once inside host macrophages, *Mtb* evades and exploits macrophage-specific defense mechanisms, induces formation of characteristic aggregates called granulomas ([@bib55]), and can persist in the face of an active immune response ([@bib56]). Virulent mycobacteria actively evade a number of cell-autonomous defense pathways ([@bib56]); mycobacteria have been reported to inhibit phagolysosome fusion ([@bib71]), manipulate cell death pathways for their own survival ([@bib66]), mediate resistance to oxidative stress ([@bib50]), as well as survive at low pH in fully acidified phagolysosomes ([@bib38]). In addition, pathogenic mycobacteria reside within specialized host structures called granulomas, a unique niche in which bacterial populations are recalcitrant to killing due to changes in bacterial physiology as well as reduced immune cell and antibiotic access ([@bib16]). Most broad screens for host-directed therapies have been limited to cell culture. While providing insight into cell-autonomous activities of potential host-directed drugs, cell culture platforms lack the multicellular interactions and complex environment present during mycobacterial disease in vivo.

Zebrafish are natural hosts of *Mycobacterium marinum*, one of the closest relatives of the *Mtb* complex ([@bib73]). *M. marinum* and *Mtb* share conserved virulence loci and induce similar host immune responses and pathology, including the formation of granulomas ([@bib17]). Genes identified in zebrafish as determinants of mycobacterial disease progression have also been associated with disease severity and outcome in humans ([@bib72]; [@bib74]). Because zebrafish larvae are optically transparent, both pathogen and host processes can be imaged in vivo in a natural host. *M. marinum* infection of larval zebrafish recapitulates key aspects of tuberculosis pathogenesis ([@bib17]). In addition, the zebrafish larva's small size and relative permeability to small molecules allow for chemical genetic screening in the context of whole animals ([@bib40]). Here, we used the zebrafish-*M. marinum* model to perform a chemical screen in whole animals for host-directed therapies during mycobacterial infection.

We identify a number of host-directed therapies with in vivo efficacy against mycobacterial infection. Among these is clemastine, a well-tolerated, broadly available, FDA-approved drug. We report that, in zebrafish, clemastine acts in vivo to enhance mycobacterial control via potentiation of the purinergic receptor P2rx7. Using light-sheet microscopy, we find that clemastine-induced potentiation of P2rx7 drives increased calcium transients within infected macrophages in vivo. P2rx7 potentiation enhances inflammasome activation, resulting in restriction of mycobacterial growth in zebrafish larvae. Finally, using a novel granuloma explant model, we show that clemastine is an effective host-directed therapy in the context of granulomas from established mycobacterial infections.

Results {#s2}
=======

An in vivo chemical screen uncovers six novel HDTs for mycobacterial infection {#s2-1}
------------------------------------------------------------------------------

To identify novel host-directed therapies that reduce mycobacterial burden in vivo, we screened the 1200 FDA-approved drugs of the Prestwick Chemical Library using zebrafish larvae infected with fluorescent *M. marinum* ([Figure 1A](#fig1){ref-type="fig"}). Three animals per well in a 96-well format were each infected with \~ 150 CFU of *M. marinum* and maintained for 5 days at a 5 µM concentration of each compound. We evaluated the efficacy of each of the 1200 compounds in reducing bacterial growth by measuring mycobacterial fluorescence in whole animals over the course of a 5-day infection. Quantitation of bacterial fluorescence driven by a stable, constitutive promoter provides a validated measure of bacterial burden in zebrafish larvae ([@bib3]; [@bib70]; [@bib77]).

![An in vivo zebrafish chemical screen identifies six novel host-directed therapies.\
(**A**) Schematic of chemical screen. 1200 compounds in the Prestwick Library were screened at a final concentration of 5 µM in 0.5% DMSO for substantial reductions in bacterial burden. Three larvae were placed in each well and imaged at 5 days post-infection (dpi). 1° denotes primary screen, 2° secondary, and 3° tertiary screens. Numerator represents number of hits after that screening step over the total number of compounds tested in that step. *Mm* = *Mycobacterium marinum* (**B**) Hits from chemical screen determined to reduce bacterial burden compared to DMSO control. All drug concentrations are 5 µM in 0.5% DMSO. Bacterial burden by fluorescence is normalized to DMSO control for each experiment. Data shown is representative of three experiments with n \> 15 animals for each experiment. Error bars are s.d. \*represents drugs with previously identified host-directed mechanism (**C--J**), Chemical structures of drugs identified as reducing bacterial burden in a host-directed manner.](elife-39123-fig1){#fig1}

From the initial screen, we identified 51 compounds that reduced mycobacterial burden in vivo. In a secondary screen of these potential hits, we found that 23 of the 51 compounds identified resulted in reduced bacterial burdens in a second set of in vivo infections, and these 23 compounds were selected for further analysis. To distinguish between drugs that directly target bacteria and those that have host-dependent effects, we treated *M. marinum* cultures with each compound and monitored bacterial growth ([Figure 1A](#fig1){ref-type="fig"}). Three compounds, each previously reported to have antimicrobial activity, exhibited direct anti-mycobacterial activity at the concentrations tested ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A--D](#fig1s1){ref-type="fig"}), validating our ability to recapitulate the effect of known anti-tubercular drugs in an in vivo model. A known antibiotic, sulfamethazine, was not effective at 5 µM in broth culture, but was effective in vivo, suggesting that in vivo distribution kinetics and/or metabolism may enhance potency. Thus, the whole animal drug screening approach was able to identify antibiotics that are effective in vivo but might be missed in screens of axenic cultures ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Due to the known antimicrobial function of sulfamethazine, we did not consider it further as a potential host-directed therapy. The Prestwick Chemical Library contains additional antimycobacterial agents that did not emerge as hits; however, a number of these compounds are ineffective in zebrafish larvae at the 5 µM concentration used during our screen ([@bib3]; [@bib70]).

Because host-directed therapies may provide new approaches to TB treatment, we focused on the subset of drugs with host-dependent activity. The 19 compounds that reduced bacterial burden in vivo but not in culture were obtained from independent sources and tested in larger cohorts. Of these 19 potential host-directed compounds, 9 resulted in consistently reduced bacterial burdens in three independent in vivo experiments but had no effect on bacterial growth in liquid broth culture ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Thus, these nine drugs met all criteria for host-dependent therapies effective in reducing burden in whole animals over 5 days of infection. One of the nine, prothionamide, appeared to be host-dependent at the concentration tested but is likely not host-directed ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}); prothionamide is a pro-drug that can be metabolized into active anti-mycobacterial forms by both bacteria and host ([@bib51]).

Of the remaining eight compounds we identified as likely to be host-directed therapies ([Figure 1C--J](#fig1){ref-type="fig"}), one drug, desipramine, had been described previously as a potential HDT; it is proposed to act through inhibition of acid sphingomyelinase, which has been implicated in necroptosis and the response to mycobacterial infection in zebrafish ([@bib59]). Chlorpromazine is known to inhibit acid sphingomyelinase, although it also has reported anti-mycobacterial activity in culture ([@bib4]). To the best of our knowledge, none of the six remaining compounds had previously been considered as a potential host-directed therapy for mycobacterial infection. We chose to focus on the most potent of these, clemastine, an inexpensive, widely available, over-the-counter antihistamine.

Clemastine is a host-directed compound that requires host macrophages to reduce bacterial growth {#s2-2}
------------------------------------------------------------------------------------------------

We found that clemastine consistently reduced mycobacterial growth in vivo over the course of a 5-day infection ([Figure 2A--B](#fig2){ref-type="fig"}). The effect was dose dependent ([Figure 2C](#fig2){ref-type="fig"}), and at a concentration of 5 µM resulted in a \~ 60% reduction in bacterial burden by 5 days post-infection (dpi). At 5 dpi, there were fewer total infection foci, and areas of infection were smaller ([Figure 2B](#fig2){ref-type="fig"}), indicating that clemastine reduces bacterial burden significantly after just a few days of infection. In culture conditions, clemastine had no effect on bacterial growth at concentrations up to 50 µM, although at higher concentrations that were toxic to larvae (100 µM), there was some reduction in bacterial growth in culture ([Figure 2D](#fig2){ref-type="fig"}). Thus, clemastine functions to reduce bacterial burden in whole animals in a host-dependent manner.

![Clemastine activity is host-dependent, dose-responsive, and requires macrophages.\
(**A**) Bacterial burden per animal assessed by *Mm:tdTomato* fluorescence 5 days post infection (dpi) after treatment with 0.5% DMSO vehicle or 5 µM clemastine. Red dots denote the corresponding image shown in [Figure 2B](#fig2){ref-type="fig"}. Representative of five experiments. (**B**) Representative images from experiment in [Figure 2A](#fig2){ref-type="fig"} (red dots). *Mm:tdTomato* infection treated with 0.5% DMSO vehicle or 5 µM clemastine in 0.5% DMSO. White arrows denote regions of bacterial foci. Scale bar is 500 µm. (**C**) Quantification of *Mm:tdTomato* fluorescence at 5 dpi in zebrafish larvae treated with increasing concentrations of clemastine. (**D**) *Mm:tdTomato* bacterial broth culture grown in the presence of increasing concentrations of clemastine, compared to 0.5% DMSO, 1% DMSO, no vehicle (-), and 200 µg/mL isoniazid. (**E**) Bacterial burden of wildtype and heterozygous siblings or *irf8^st95^* mutants, which lack macrophages, treated with 0.5% DMSO or 5 µM clemastine. Blue dots indicate animals in [Figure 2F](#fig2){ref-type="fig"}. Data are pooled from two biological replicates. (**F**) Representative infections from *irf8^st95^* mutants and wildtype/heterozygous siblings from each treatment group in [Figure 2E](#fig2){ref-type="fig"} at 5 dpi. Wildtype animals (left) were equally brightened (no change in gamma settings) to show contrast of bacteria and brightfield. The *irf8^st95^-/-* example animals (right) were not brightened. (**G**) Number of bacteria per macrophage during treatment with 0.5% DMSO or 5 µM clemastine, 1 dpi. Each dot represents the mean number of intracellular *Mm:mCerulean* bacteria inside macrophages of one *Tg (mfap4:tdTomato)^xt11^* animal at 24 hpi infected with \~ 50 CFU. Representative of three independent experiments. (**A**) Two-tailed, unpaired t-test. (**C**) Ordinary one-way ANOVA with Tukey's multiple comparison test, ns^1 ^= 0.0864, ns^2 ^= 0.7799, ns^3 ^= 0.2415. Post-test for linear trend, p\<0.0001. (**E**) Kruskal-Wallis ANOVA for unequal variances with Dunn's multiple comparisons test, ns^1 ^\> 0.9999 (**A,C,E**) Error bars are s.d. (**G**) Two-tailed unpaired t-test; error bars are s.e.m. p-Values from statistical tests on untransformed data are provided in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.](elife-39123-fig2){#fig2}

Clemastine's mechanism of action was unlikely to be attributable to its antihistamine activity. Of the 41 antihistamines in the Prestwick Chemical Library, only one other in a separate class, trimeprazine, was identified as a hit. In addition, diphenhydramine, another antihistamine of the same family as clemastine, had no effect on bacterial burden ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Thus, we hypothesized that clemastine's host-directed antimycobacterial activity was due to a distinct effect of the drug unrelated to its antihistamine activity.

Macrophages are central host cells in mycobacterial infection in humans and animal models, including zebrafish ([@bib10]; [@bib56]). To test whether clemastine acts via macrophages to reduce bacterial burden, we treated infected, macrophage-deficient animals with clemastine. Mutations in the gene encoding the myeloid transcription factor Irf8 result in an absence of larval macrophages, due to impaired differentiation from myeloid precursors ([@bib64]). In *irf8* mutants, similar to other macrophage-deficient animals, bacterial burdens are higher, with extracellular bacterial growth ([@bib54]). We found that clemastine was ineffective in *irf8*-deficient animals ([Figure 2E--F](#fig2){ref-type="fig"}), suggesting that clemastine's action requires functional macrophages.

We next took advantage of the ability to perform high-resolution, longitudinal imaging in the zebrafish to understand how clemastine alters mycobacterial infections within macrophages in vivo. The zebrafish infection model enables quantitation of intracellular growth in vivo through direct enumeration of bacterial burden and replication in individual macrophages ([@bib70]). Host mutations that compromise the ability of macrophages to restrict intracellular mycobacterial growth result in higher numbers of bacteria per macrophage, while bacterial mutants attenuated for intracellular growth exhibit reduced bacterial numbers within each macrophage ([@bib70]). We used a cerulean fluorescent *M. marinum* strain to infect the zebrafish transgenic line *Tg(mfap4:tdTomato)^xt12^* ([@bib76]), in which macrophages are fluorescently labeled red, and quantified intracellular bacterial growth during clemastine treatment ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Clemastine treatment for 24 hours reduced the number of bacteria per macrophage by \~ 30%, suggesting that clemastine enhances control of mycobacterial infection at the level of individual infected macrophages, even before formation of granulomas ([Figure 2G](#fig2){ref-type="fig"}). Importantly, clemastine did not alter the total number of macrophages per animal ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}).

To distinguish between growth restriction and a microbicidal effect, we performed long-term live imaging, focusing on individual macrophages within infected animals. Clemastine-treated animals consistently showed loss of bacterial fluorescence within macrophages, while control-treated animals did not, suggesting that clemastine enhances the microbicidal activity of macrophages ([Video 1](#video1){ref-type="video"}, [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). Together, these findings are consistent with a macrophage-dependent mechanism in which macrophage-induced mycobacterial killing is enhanced upon clemastine administration.

###### Clemastine treatment results in clearing of bacteria by host macrophages.

Split screen video of the caudal hematopoietic tissue of a *Tg(mfap4:tdTomato-CAAX)^xt6^* (false colored magenta) zebrafish larva infected with \~50 CFU of *Mm:mCerulean.* Left side of the screen is an animal treated with 0.5% DMSO. Right side is an animal treated with 5 µM clemastine. In vivo timelapse is 17--34 hr post infection, with frames every 10 min. Maximum intensity projection of 4 z stacks of 15 μm, 30 frames per second. Stills of single channels are in [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}.

10.7554/eLife.39123.006

Pathogenic mycobacteria can limit acidification of the phagosome, creating a replicative niche within macrophages ([@bib60]). We sought to determine if clemastine increased the acidification of mycobacteria-containing phagosomes. The reporter *aprA'::gfp* has been used to probe acidification in mycobacteria ([@bib2]). The promoter of *aprA* is pH-inducible and drives expression of GFP only under acidic conditions (pH \<6). Simultaneous visualization of the inducible GFP and mCherry expression from the constitutive promoter *smyc* (*smyc'::mCherry*), allows visualization of the acidification state of bacteria in vivo. We measured the ratio of green fluorescence to red fluorescence in *M. marinum aprA'::GFP,smyc'::mCherry* infections in vivo and observed that clemastine did not increase the proportion of bacteria that induce the *aprA* reporter ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}), indicating that clemastine likely does not act through increased rates of phagosome acidification.

Clemastine enhances calcium transients in infected macrophages, and its activity is dependent on P2RX7 {#s2-3}
------------------------------------------------------------------------------------------------------

P2RX7 is a ligand-gated cation channel activated by extracellular ATP, which is found at sites of infection and injury ([@bib19]). In humans, mice, and fish, P2RX7 is highly expressed on immune cells ([@bib19]; [@bib30]). One cell culture study had reported that clemastine can potentiate human P2X7 receptor (P2RX7) activity ([@bib52]). We hypothesized that, in vivo, clemastine's effect on mycobacterial infection burden might involve potentiation of P2RX7.

Using CRISPR/Cas9-based targeting, we isolated and outcrossed two different alleles predicted to abolish the second transmembrane domain of zebrafish P2RX7 receptor (P2rx7) ([Figure 3A--B](#fig3){ref-type="fig"}). Both alleles (*p2rx7^xt26^* and *p2rx7^xt28^*) result in frameshifts in exon 10 and predicted stop codons upstream of the second transmembrane domain, suggesting that both alleles are functional nulls ([@bib65]). We then examined whether these mutations affected responsiveness to clemastine treatment. Given P2RX7's known role as a calcium channel, we first assessed intracellular calcium dynamics within macrophages in vivo during clemastine treatment.

![Clemastine increases frequency of macrophage calcium transients in a *p2rx7*-dependent manner.\
(**A**) Schematic of P2rx7 receptor, based on human structure, with CRISPR target site in exon 10 denoted with a star. (**B**) CRISPR/Cas9-mediated lesions in *p2rx7* include a five base pair deletion (*p2rx7^xt26^*) and a two base pair deletion (*p2rx7^xt28^*) leading to a premature stop codon in exon 10. Red bar denotes *p2rx7* mutants and blue bar denotes WT animals. (**C**) Quantification of calcium flashes observed with light-sheet microscopy in *Tg(mfap4:GCaMP6F*)*^xt25^* and *p2rx7^xt26^;Tg(mfap4:GCaMP6F)^xt25^* infected with \~ 50 CFU *Mm:tdTomato*. Each dot represents the number of flashes observed in a single infected macrophage in an animal during a 30-min time-course during treatment with 0.5% DMSO or 5 µM clemastine, 4--5 hpi, n \> 3 fish for each group. All cells counted were visibly infected with *Mm:tdTomato* and scoring performed blind to genotype or treatment. (**D**) Representative calcium transient. Panels are stills from a light-sheet video in an untreated *Tg(mfap4:GCaMP6F*)*^xt25^* animal infected with *Mm:tdTomato*. Scale bar is 25 µm. (**C**) Kruskal-Wallis ANOVA for unequal variances, Dunn's multiple comparison test. ns^1^ \> 0.9999, ns^2^ = 0.7007 All error bars are s.d.; p values from statistical tests on untransformed data are provided in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.](elife-39123-fig3){#fig3}

To examine clemastine's effect on macrophage calcium dynamics in vivo, we generated the zebrafish transgenic line *Tg(mfap4:GCaMP6F)^xt25^* in which the genetically encoded calcium indicator GCaMP6F is driven by a macrophage-specific promoter ([@bib8]; [@bib76]). Using light-sheet microscopy, we were able to examine macrophage calcium dynamics in whole animals in vivo during infection. Although calcium dynamics during mycobacterial infection have previously been studied in cultured macrophages, they have not been assessed in vertebrate models in vivo. We found that both infected and uninfected macrophages in the caudal area underwent stereotypical calcium flashes ([Figure 3C--D](#fig3){ref-type="fig"}) at \~ 0.1 flashes per minute ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}, [Video 2](#video2){ref-type="video"}). Administration of clemastine significantly enhanced the frequency of these macrophage calcium transients more than two-fold in infected cells ([Figure 3C](#fig3){ref-type="fig"} and [Video 3](#video3){ref-type="video"}).

###### Wildtype and *p2rx7* mutants exhibit similar calcium transients in uninfected larvae.

Split screen video of *Tg(mfap4:GCaMP6F)^xt25^* (left) and *p2rx7^xt26^;Tg(mfap4:GCaMP6F)^xt25^* (right) uninfected larvae, 2 days post fertilization (dpf). 30 min light-sheet microscopy timelapse, acquiring every 8.8 s. Maximum intensity projection of 80 steps of 1 μm, 30 frames per second. Flashes are marked with either a circle (WT) or a square frame (mutant). Yellow frames represent cells that only flash once. Other colors (white, green, blue, red, green, cyan) represent cells that flash more than once, with the same cell marked in the same color throughout the timelapse. Only cells that are present during the whole video are marked. Whole cell flashes, not subcellular flickers, are marked.

10.7554/eLife.39123.009

###### Clemastine enhances calcium transients in wildtype infected zebrafish larvae.

Split screen video of *Tg(mfap4:GCaMP6F)^xt25^*larval zebrafish 2 dpf, infected with \~ 50 CFU. *Mm:TdTomato*, 4 hr post infection, treated with 0.5% DMSO (left) or 5 µM clemastine (right). 30 min light-sheet microscopy timelapse, acquiring every 8.8 s. Maximum intensity projection of 80 steps of 1 μm, 30 frames per second. Flashes are marked with either a circle or a square frame. Yellow frames represent cells that only flash once. Other colors (white, green, blue, red, green, cyan) represent cells that flash more than once, with the same cell marked in the same color throughout the timelapse. Only cells that are present during the whole video are marked. Whole cell flashes, not subcellular flickers, are marked.

10.7554/eLife.39123.010

Given the known role of P2RX7 in mediating calcium influx, we next tested whether the enhancement of calcium transients we observed with clemastine in vivo was dependent on P2r×x7. We crossed the macrophage calcium reporter line into the *p2rx7^xt26^* background (*p2rx7^xt26^;Tg(mfap4:GCaMP6F)^xt25^*) and quantified calcium transients in macrophages within whole animals by light-sheet microscopy ([Videos 2](#video2){ref-type="video"}--[4](#video4){ref-type="video"}); we observed no differences in calcium dynamics between wildtype and *p2rx7* mutant fish at baseline ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}, [Video 2](#video2){ref-type="video"}). In infected wildtype animals, clemastine increased the frequency of calcium transients more than two-fold, but this effect was abrogated in *p2rx7* mutants ([Figure 3C](#fig3){ref-type="fig"}). Clemastine did not significantly increase calcium transients in uninfected cells in infected fish ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Thus, clemastine's enhancement of calcium transients in *Mycobacterium-*infected cells may occur through potentiation, rather than direct agonism of P2rx7.

###### Clemastine does not enhance calcium transients in *p2rx7* mutant infected zebrafish larvae.

Split screen video of *p2rx7^xt26^;Tg(mfap4:GCaMP6F)^xt25^* larval zebrafish two dpf, infected with \~ 50 CFU *Mm:TdTomato*, 4 hr post infection, treated with 0.5% DMSO (left) or 5 µM clemastine (right). 30 min light-sheet microscopy timelapse, acquiring every 8.8 s. Maximum intensity projection of 80 steps of 1 μm, 30 frames per second. Flashes are marked with either a circle or a square frame. Yellow frames represent cells that only flash once. Other colors (white, green, blue, red, green, cyan) represent cells that flash more than once, with the same cell marked in the same color throughout the timelapse. Only cells that are present during the whole video are marked. Whole cell flashes, not subcellular flickers, are marked.

10.7554/eLife.39123.011

Clemastine's anti-mycobacterial activity is dependent on *p2rx7* {#s2-4}
----------------------------------------------------------------

Having established a dependence of clemastine-enhanced calcium flux on *p2rx7*, we next sought to determine if the accompanying reduction in bacterial burden was also *p2rx7* dependent. Using *p2rx7^xt26^* and *p2rx7^xt28^* mutant larvae and wildtype siblings, we tested clemastine's effect on bacterial burden over the course of a 5-day infection. *p2rx7* mutants did not show significant differences in overall bacterial burden, although there was a slight decrease in bacterial burden in *p2rx7* mutants ([Figure 4A](#fig4){ref-type="fig"}). Clemastine consistently reduced burden in wildtype animals but failed to reduce bacterial burden in *p2rx7* mutants ([Figure 4A--B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}). Thus, both the altered macrophage calcium dynamics and reduction in bacterial burden were dependent on functional P2rx7.

![The effect of clemastine on bacterial burden is *p2rx7* dependent.\
(**A**) Quantification of *Mm:tdTomato* fluorescence at 5 days post-infection (dpi) in wildtype and *p2rx7^xt26^* larvae treated with 0.5% DMSO or 5 µM clemastine, infected with \~ 100--150 CFU. Blue bar denotes wildtype larvae and red denotes *p2rx7*^*xt26*^ mutants. Red and blue dots denote the corresponding image shown in (**B**). Representative of 12 independent experiments, with \> 15 fish per group, presented in [Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}. (**B**) Representative fish from each treatment group in [Figure 4A](#fig4){ref-type="fig"}, 5 dpi. Blue bar labels wildtype \*AB fish; red bar labels *p2rx7^xt26^*. Scale bar is 500 µm. White arrows mark regions of bacterial foci. (**A**) Ordinary one-way ANOVA, Tukey's multiple comparison test, ns^1 ^= 0.9862, ns^2 ^= 0.5662, ns^3 ^= 0.2451, ns^4^ = 0.1652, ns^5 ^= 0.2375. All error bars are s.d.; p values from statistical tests on untransformed data are provided in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.](elife-39123-fig4){#fig4}

Quantitation of bacterial fluorescence has been validated as an accurate measure of bacterial burden in the zebrafish larval model ([@bib3]; [@bib70]; [@bib77]). However, we also analyzed burden using an independent assay. We quantitated mycobacterial 16S rRNA in a separate set of experiments and obtained similar results. Here, qRT-PCR revealed a \~ 0.5 log~10 ~decrease with no effect in *p2rx7^xt26^* knockout animals ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}).

Clemastine activity requires cytosolic sensing and a functional inflammasome {#s2-5}
----------------------------------------------------------------------------

As a key second messenger, calcium is required for a variety of in vivo processes that may lead to increased microbicidal activity, including endosomal trafficking ([@bib21]) and inflammasome activation ([@bib23]; [@bib48]). Our previous findings on unaltered acidification of mycobacteria in clemastine-treated animals ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}) led us to next consider inflammasome activation as a possible mechanism.

P2RX7 signaling has been shown to promote inflammasome activation ([@bib21]; [@bib57]), which can result in killing of intracellular pathogens ([@bib23]; [@bib24]; [@bib47]). Activation of inflammasomes is dependent on cytosolic sensing of PAMPs or DAMPs ([@bib36]). Pathogenic mycobacteria secrete a variety of effector proteins that access the host cytosol, presumably through permeabilization of the phagosomal membrane; cytosolic access is dependent on the specialized secretion system ESX-1 ([@bib11]; [@bib33]; [@bib41]; [@bib78]). Because P2RX7 signaling has been closely linked to inflammasome activation, we first sought to investigate if cytosolic access is required for clemastine's effect.

Pathogenic mycobacteria have been reported to both activate and limit inflammasome activation, depending on the infection model used ([@bib7]). Mycobacteria lacking the RD1 region, which encompasses the ESX-1 type VII secretion system, fail to engage cytosol-based host responses ([@bib1]; [@bib20]; [@bib75]). We infected zebrafish with a *M. marinum* strain lacking the RD1 region (∆RD1) ([@bib75]) and asked whether clemastine retained efficacy in the absence of engagement with the host cytosol. In contrast to its effect on wildtype *M. marinum,* clemastine had no effect on burden in the ∆RD1 mutants ([Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}).

![Clemastine efficacy requires cytosolic access and inflammasome signaling.\
(**A**) Quantification of bacterial burden of *Mm:Wasabi* and *Mm*ΔRD1:*Wasabi* in wildtype larvae treated with 0.5% DMSO or 5 µM clemastine, five dpi. Representative of three independent experiments. Each dot represents an individual animal's bacterial burden by fluorescence. Red dots denote the animals represented in [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}. (**B**) Quantification of bacterial burden of *Mm:tdTomato* in *pycard* (*asc*) mutants and wildtype/heterozygous siblings after 0.5% DMSO or 5 µM clemastine treatment, 5dpi. Each dot represents an individual animal's bacterial burden by fluorescence. Representative of three independent experiments. Blue (WT/het) and purple (*asc* mutants) dots denote representative larvae in [Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}. Fold change over DMSO for each genotype is presented in [Figure 5---figure supplement 2C](#fig5s2){ref-type="fig"}. (**A**) Ordinary one-way ANOVA with Tukey's multiple comparison test. All error bars are s.d. ns^1^ \> 0.9999, ns^2^ = 0.9452, ns^3^ = 0.9430. (**B**) One-way ANOVA with Tukey's multiple comparison test. All error bars are s.d. ns^1^ = 0.9998, ns^2^ = 0.5798, ns^3^ = 0.3723. p Values from statistical tests on untransformed data are provided in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.](elife-39123-fig5){#fig5}

As expected, *M. marinum* ∆RD1 mutants were attenuated during infection, and displayed reduced burden at later timepoints despite equivalent inocula. We therefore wanted to rule out the explanation that clemastine's effect was merely dependent on burden. In order to test whether clemastine is effective on infections with lower bacterial load, we infected larval zebrafish with a second attenuated mycobacterial strain. We found that *M. marinum* transposon mutants in the gene *cmaA2*, which encodes a trans-cyclopropane synthetase ([@bib26]), were attenuated in the zebrafish model. Despite a burden comparable to the ∆RD1 mutants ([Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}), clemastine still was able to reduce bacterial load, suggesting that the RD1-dependent effect was not merely due to differences in burden.

Reciprocally, when we increased the inoculum of ∆RD1 mutant bacteria above wildtype levels, clemastine is still ineffective ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). This was true using independent measures of bacterial burden at five dpi including fluorescence ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) and 16S rRNA-based measures of burden ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Additionally, we examined early control of bacterial growth in ∆RD1 infections. During the first 24 hr of infection, clemastine reduced the number of WT bacteria per macrophage ([Figure 2G](#fig2){ref-type="fig"} and [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}) but failed to reduce the number of bacteria per macrophage in the ∆RD1 infection ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). These data are consistent with a model in which clemastine efficacy requires a host defense pathway dependent on cytosolic engagement, regardless of bacterial load.

Given the ∆RD1 result, *p2rx7* dependence, and the links to calcium signaling and inflammasome activation, we next directly tested whether inflammasome activation might be required downstream of P2rx7 activation to promote mycobacterial restriction. We focused on the common adaptor ASC, which is required for inflammasome assembly in humans, mice, and zebrafish ([@bib34]; [@bib36]). We generated *asc* mutant zebrafish (zebrafish gene name *pycard*) using TALEN technology and generated a 14 base pair deletion allele, *pycard^w216^*, in the first exon of the zebrafish *asc* orthologue ([Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}), resulting in a premature stop codon. As in mice, ASC-deficient animals do not exhibit dramatically increased susceptibility to mycobacterial infection ([Figure 5B](#fig5){ref-type="fig"}). Animals had similar burdens at five dpi, similar numbers of infection foci, and displayed no gross differences during mycobacterial infection ([Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}). However, while clemastine reduced burden in wildtype and heterozygous sibling control animals, it was completely ineffective in zebrafish *asc* mutants ([Figure 5B](#fig5){ref-type="fig"}, [Figure 5---figure supplement 2B--C](#fig5s2){ref-type="fig"}). These results are consistent with a model in which inflammasome activation may be limited during infection with pathogenic mycobacteria, but enhancement can lead to increased bacterial killing.

To rule out the possibility that the clemastine effect was mediated via a previously reported connection between P2RX7 and autophagy ([@bib43]), we tested the effect of clemastine on autophagy in vivo during mycobacterial infection. We made use of the zebrafish reporter line *Tg(hCMV-GFP:Lc3)* ([@bib29]). In this line, GFP-positive puncta are indicative of autophagosomes and can be enumerated during infection and treatment with DMSO or clemastine. Using spinning disk confocal microscopy, we observed that clemastine treatment does not enhance the number or frequency of LC3-decorated mycobacteria over the course of three days of infection ([Figure 5---figure supplement 2D](#fig5s2){ref-type="fig"}). These findings are in agreement with the observed lack of change in acidification of mycobacteria, suggesting that autophagy is not the host-directed mechanism through which clemastine reduces bacterial burden in vivo.

Clemastine is effective in established infections {#s2-6}
-------------------------------------------------

We next examined whether clemastine was an effective host-directed therapy in established infections and whether it could function therapeutically in more complex, established granulomas. Adult zebrafish granulomas share key features with human *Mtb* granulomas, including a caseous necrotic core and a tight epithelialized layer that alters bacterial physiology and may restrict access to drugs ([@bib13]; [@bib37]; [@bib69]). To directly examine clemastine's efficacy in mature, established granulomas, we made use of a novel granuloma explant model, termed Myco-GEM ([@bib14]). Briefly, adult animals are infected and granulomas are dissected after 2--4 weeks of infection and cultured ex vivo for a week. Because adult zebrafish are not optically transparent, this explant approach allows live visualization of granuloma and bacterial dynamics within a mature, established granuloma that contains multiple cell types. Upon multi-day (5--7 days) treatment with clemastine, we found a nearly 70% reduction in mycobacterial fluorescence relative to vehicle control granulomas, suggesting that clemastine has efficacy both in established infections (\>2 weeks post infection) and in the context of a mature granuloma ([Figure 6A--B](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A--B](#fig6s1){ref-type="fig"}).

![Clemastine reduces bacterial growth in granuloma explants.\
(**A**) Representative granuloma explants treated with 5 µM clemastine or 0.5% DMSO from wildtype or *p2rx7^xt26^* adult animals (2 weeks post-infection) at zero days post treatment (dpt) and 5 dpt. Animals were infected with \~300 CFU *Mm:mCerulean.* Blue line denotes granulomas from wildtype adult fish and red line denotes granulomas from *p2rx7^xt26^* adult fish. Images are maximum intensity projections of spinning disk confocal images, 15 steps of 10 µm. DIC and *Mm:mCerulean* channels are merged. Quantification in [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}, averages from this experiment are denoted in the green squares of [Figure 6B](#fig6){ref-type="fig"}. (**B**) Quantification of 6 independent experiments in which *Mm:mCerluean* fluorescence at 5dpt is normalized to the DMSO treatment of wildtype granuloma explants. Each dot is the average bacterial burden at 5 dpt for each treatment group, normalized to the experiment's wildtype explants treated with DMSO. Bacterial burdens per experiment are color-coded (e.g. red dots are all from the same experiment). Squares represent granulomas from *p2rx7^xt28^* adult infections and circles represent granulomas from*p2rx7^xt26^* adult infections. The blue line represents wildtype animals and the red line represents *p2rx7* mutants. Fold change of bacterial burden over DMSO-treated granulomas for each genotype is in [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"} using the same colors for each experiment. (**C**) Quantification of FLICA-positive cells from FACS analysis after treatment with DMSO or 5 µM clemastine 2 dpt. Each dot represents the treatment averages from an independent experiment, normalized to the DMSO treatment for each experiment with at least three biological replicates per experiment. Gating strategy provided in [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"} and individual experimental averages in [Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}. (**D**) Quantification by luminescence of *Mm:Lux* granulomas 7 dpt after treatment with 0.5% DMSO or 5 µM clemastine, with each dot representing a single experiment's average luminescence for each treatment. Luminescence values are color-coded between experiments. Granuloma explants used for CFU plating are colored with green dots and represented in [Figure 6E](#fig6){ref-type="fig"} as green dots. Fold change of bacterial burden over DMSO-treated granulomas in each treatment is in [Figure 6---figure supplement 3A](#fig6s3){ref-type="fig"}. (**E**) Quantification of bacterial load by colony-forming units (CFU) 8 dpt with DMSO or 5 µM clemastine. Each dot represents a single granuloma. Fold change of bacterial burden over DMSO-treated granulomas in each treatment is in [Figure 6---figure supplement 3A](#fig6s3){ref-type="fig"}. (**F**) Quantification by luminescence of *Mm:Lux* granulomas seven dpt after treatment with 0.5% DMSO, 5 µM clemastine, 2 µg/mL moxifloxacin, or combination clemastine and moxifloxacin. Data are pooled from two experiments. Fold change of bacterial burden over DMSO-treated granulomas in each treatment is in [Figure 6---figure supplement 3C](#fig6s3){ref-type="fig"}. (**B**) Friedman Test (paired) ANOVA with Dunn's multiple comparisons test ns^1 ^\> 0.9999, ns^2^ = 0.1521. All error bars are s.e.m. (**C**) Unpaired t-test, error bars are s.e.m. (**D**) Paired t-test, error bars are s.e.m. (**E**) Unpaired t-test, error bars are s.d. (**F**) Kruskal-Wallis ANOVA with Dunn's multiple comparisons test, ns^1 ^\> 0.9999. All error bars are s.d. p-Values from statistical tests on untransformed data are provided in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.](elife-39123-fig6){#fig6}

Consistent with the larval experiments, we found that clemastine enhanced activation of inflammasome-dependent pathways. We used a FLICA reagent (ImmunoChemistry Technologies) that covalently binds a fluorophore to activated caspase-1; the fluorescent signal is a direct readout of caspase-1 activation. Using this tool and flow-cytometry methods developed for Myco-GEM ([@bib14]), we found that clemastine treatment significantly increased the percentage of cells positive for FLICA relative to the DMSO control ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2A--C](#fig6s2){ref-type="fig"}).

To obtain an independent longitudinal readout of bacterial burden during treatment of established infections, we constructed a bioluminescent strain of *M. marinum, M. marinum:Lux* ([@bib14]). We introduced a plasmid containing a bacterial luciferase operon ([@bib6]) into the reference strain and infected adult animals. After 2 weeks, we dissected and cultured established granulomas, monitoring luminescence daily in the presence of clemastine or vehicle. Clemastine-treated granulomas had a nearly 10-fold reduction in luminescence relative to control granulomas after 6 days of treatment ([Figure 6D](#fig6){ref-type="fig"}, [Figure 6---figure supplement 3A](#fig6s3){ref-type="fig"}), suggesting that the effect size may be greater than that observed by fluorescence-based readouts. To ensure that clemastine did not quench bioluminescent signals, we treated *M. marinum:Lux* with clemastine in broth culture and saw no effect on luminescence compared to DMSO carrier ([Figure 6---figure supplement 3B](#fig6s3){ref-type="fig"}). Thus, clemastine has substantial efficacy as a host-directed therapy both in larvae and in more complex, established granulomas.

To further validate the readout of luminescence and fluorescence in the Myco-GEM model, we plated individual granulomas for colony forming units (CFU). We found that clemastine treatment significantly reduced CFU by \~ 1.4 log~10~ (\~ 27 fold) compared to vehicle-exposed granulomas after a week of Myco-GEM culture ([Figure 6E](#fig6){ref-type="fig"}, [Figure 6---figure supplement 3A](#fig6s3){ref-type="fig"}).

Host-directed therapies will likely be used as adjunctive therapies in the context of antibiotic treatment. Therefore, HDTs should not limit the effects of antibiotics and should further reduce bacterial load. We have previously found that moxifloxacin has reduced effectiveness against mycobacteria in cultured granulomas relative to mycobacteria cultured in vitro ([@bib14]). Using granulomas infected with *M. marinum:Lux,* we tested clemastine's effect in the presence of moxifloxacin. Clemastine treatment significantly enhanced the effect of moxifloxacin in Myco-GEM granulomas ([Figure 6F](#fig6){ref-type="fig"}, [Figure 6---figure supplement 3C](#fig6s3){ref-type="fig"}), suggesting that it can act as a combination host-directed therapy with other antibiotics in the context of a complex, established infection.

Discussion {#s3}
==========

One of the major causes of TB mortality is mycobacterial resistance to killing by standard antibiotics. Humans require multi-drug regimens and prolonged duration of treatment for active disease, increasing the risk for inadequate or discontinued treatments and the emergence of antibiotic resistance. Multi-drug resistant strains (which require 9--24 months of treatment, including use of an injectable agent) were responsible for an estimated 480,000 new TB cases in 2014, with an estimated treatment failure rate of 46% ([@bib80]). Thus, new treatment strategies are urgently needed.

We performed a 1200 compound chemical genetic screen of FDA-approved drugs for host-directed therapies against mycobacterial infection using a whole animal platform. Large drug screens in whole animals would be extremely challenging in other vertebrates, but the small size, relative permeability, and fecundity of zebrafish enable high-throughput chemical screens.

Using the zebrafish model, we were able to identify in vivo activity of the drug clemastine on the purinergic receptor P2rx7 during mycobacterial infection in zebrafish. We established transgenic lines to monitor calcium dynamics within macrophages during mycobacterial infection in vivo and found complex patterns of calcium transients. Interestingly, the frequency of calcium transients in zebrafish macrophages is similar to what has been reported for infected *Drosophila* macrophages in vivo ([@bib79]).

We identified an important moonlighting activity for clemastine in mycobacterial infection: potentiation of the purinergic receptor, P2RX7. That target, P2RX7, has been implicated in a variety of inflammatory and immune processes; its activation can result in bacterial killing in cell culture ([@bib12]; [@bib21]; [@bib62]) (reviewed in [@bib19]). Mawatwal *et al* have reported that calcimycin induces P2RX7 dependent autophagic killing of *M. smegmatis* and BCG in cell culture ([@bib43]). However, we did not see enhancement of autophagy in clemastine-treated animals, suggesting that this is not clemastine's mode of action. Intriguingly, polymorphisms in the P2RX7 receptor have been associated with TB susceptibility in humans ([@bib39]; [@bib81]) and functional changes contribute to TB pathogenesis in some cell culture models but have given divergent results in different mouse models ([@bib5]; [@bib49]; [@bib62]). In cell culture, P2RX7 activation enhances mycobacterial killing in an ATP-dependent manner ([@bib58]), and these findings are consistent with our in vivo data with clemastine and P2RX7 activation.

Here, however, the in vivo drug screen uncovered a novel approach to modulating P2RX7 during mycobacterial infection. While previous studies have focused on the effects of loss of function of P2RX7, we show that direct potentiation of the channel enhances host control of infection. In addition, rather than constitutive activation, this mechanism avoids potential off-site detrimental effects. Potentiation of an ATP-responsive channel rather than constitutive activation thus represents a more nuanced approach to enhancing the host immune response and may avoid problems associated with excessive or inappropriate macrophage activation ([@bib22]). Supporting the notion of a localized and infection-specific effect of the drug, only infected cells exhibited increased calcium transients during clemastine treatment.

P2RX7 activation has been strongly linked to inflammasome activation ([@bib18]), but there is divergent evidence for the precise roles of inflammasome signaling during mycobacterial infection ([@bib7]; [@bib44]). In mycobacterial mutants lacking ESX-1, there is a drastic reduction in IL-1B production in vitro, with effects on the AIM2 inflammasome ([@bib78]). Others have shown that non-virulent mycobacteria increase inflammasome activation compared to virulent strains ([@bib63]). We showed that clemastine is ineffective against mycobacteria lacking the ESX-1 locus, leading us to initially explore the hypothesis that inflammasome signaling might be required for clemastine's effect in vivo.

To test this directly, we developed and assessed a zebrafish mutant that lacks the critical adaptor protein Asc. Consistent with findings in mice, the zebrafish *asc* larvae had no significant differences in mycobacterial burden ([@bib44]). However, mutations in other key inflammasome genes enhance susceptibility to mycobacterial infections in animal models, indicating that inflammasomes can be involved in host protection ([@bib25]; [@bib32]). Notably, we show that clemastine is completely ineffective in inflammasome-deficient animals, supporting a model in which inflammasome signaling can be host-beneficial. Thus, inflammasome activation through P2rx7 potentiation may enhance mycobacterial killing, potentially by overcoming bacterially mediated inhibition. While excess stimulation of inflammasome signaling has also been shown to be host-detrimental ([@bib46]), there may be differences between a more nuanced and localized potentiation of the P2RX7 response to ATP and more general enhancement of inflammasome activation.

As FDA-approved compounds, drugs identified using this approach have the potential to move quickly into the clinic. Indeed, the most promising compound identified in our screen, clemastine, is inexpensive, widely available, and has few known safety risks. Clemastine recently showed promise in a clinical trial for patients with multiple sclerosis ([@bib27]), and -- due to its safety profile -- would be a prime candidate for low-risk/high-reward studies in humans.

Clemastine is effective both in early infections in zebrafish larvae and in longer term, established infections. Using a granuloma explant model, we found improved control of mycobacterial infection, suggesting therapeutic efficacy in established infections and within complex granulomas, the key host-pathogen interface in mycobacterial infections across natural host species. Taken together, these data suggest a model ([Figure 7](#fig7){ref-type="fig"}) in which clemastine reduces intracellular bacterial burden through potentiation of the purinergic receptor P2rx7 to induce inflammasome activation in both nascent and established mycobacterial infections. Thus, modulation of a P2RX7 inflammasome axis is a promising avenue for host-directed therapies against mycobacterial infection in established disease. Further understanding of the mechanistic basis for P2RX7-mediated mycobacterial control, as well as ways in which inflammasome activation can be modulated at discrete points in infection, may lead to new approaches to host-directed therapies.

![A model describing clemastine as a host-directed drug against mycobacterial infection in both nascent and established infections.\
Clemastine potentiates the purinergic channel, P2rx7, to increase calcium transients within infected macrophages. Clemastine enhances microbicidal activities within macrophages to kill intracellular bacteria (**A, B**) in a manner that requires *p2rx7* (**C**), intact mycobacterial ESX-1 (**D**), and a functional inflammasome (**E**).](elife-39123-fig7){#fig7}

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                 Designation           Source or\                                                            Identifiers         Additional\
  (species) or\                                       reference                                                                                 information
  resource                                                                                                                                      
  ----------------------------- --------------------- --------------------------------------------------------------------- ------------------- -------------
  Gene\                         Lux                   Addgene,\                                                             ID_Addgene:\        
  (*Mycobacterium*\                                   ([@bib6]).                                                            pMV306hsp           
  *marinum* + *Photorhabdus*\                                                                                                                   
  *luminescens*)                                                                                                                                

  Strain, strain\               \*AB                  <https://zfin.org/ZDB-GENO-960809-7>                                                      
  background\                                                                                                                                   
  (*Danio rerio*)                                                                                                                               

  Genetic reagent\              *mfap4:*\             this paper                                                                                
  (*Danio rerio*)               *GCaMP6F^xt25^*                                                                                                 

  Genetic reagent\              *p2rx7^xt26^*         this paper                                                                                
  (*Danio rerio*)                                                                                                                               

  Genetic reagent\              *p2rx7^xt28^*         this paper                                                                                
  (*Danio rerio*)                                                                                                                               

  Genetic reagent\              *asc^w216^*           this paper                                                                                
  (*Danio rerio*)                                                                                                                               

  Genetic reagent\              *mfap4:tdTomato*      [@bib76],\                                                                                
  (*Danio rerio*)                                     <https://doi.org/10.1371/journal.pone.0138949>                                            

  Genetic reagent\              *cmaA2*               this paper                                                                                
  (*Mycobacterium marinum*)                                                                                                                     

  Genetic reagent\              *$\Delta$RD1*         [@bib75],\                                                                                
  (*Mycobacterium marinum*)                           <https://doi.org/10.1371/journal.pbio.0020367>                                            

  Commercial\                   FLICA                 ImmunoChemistry\                                                      ID_Immuno\          
  assay or kit                                        Technologies                                                          Chemistry\          
                                                                                                                            Technologies:9122   

  Chemical\                     Clemastine\           Sigma                                                                 ID_Sigma:SML0445    
  compound, drug                fumarate                                                                                                        

  Software, algorithm\          ImageJ                [@bib61]                                                                                  
  other, Chemical\                                                                                                                              
  Screening Platform                                                                                                                            

  Other, Chemical\              Prestwick Chemical\   <http://www.prestwickchemical.com/libraries-screening-lib-pcl.html>                       
  Screening Platform            Library                                                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

Animal handling and maintenance {#s4-1}
-------------------------------

All zebrafish procedures and husbandry complied with policies by the Duke University Institutional Animal Care and Use Committee (protocol A122-17-05). Eggs were collected from in-tank spawning and kept in 1X E3 medium (5 mM CaCl, 178 μM KCl, 328 μM CaCl~2~, 400 μM MgCl~2~ in dH~2~O) at 28.5°C. Pigmentation was prevented using 1-phenyl-2-thiourea (PTU; Alfa Aesar L06690; 45 μg/mL), beginning treatment at one dpf. Unless otherwise noted, all zebrafish are in the \*AB wildtype strain.

Transgenic lines {#s4-2}
----------------

The transgenic line *Tg(mfap4:tdTomato)^xt12^* and *Tg(mfap4:tdTomato-CAAX)^xt6^* have been previously described ([@bib76]). *irf8^st95^* mutant zebrafish are described elsewhere ([@bib64]). Creation and validation of the *tnf:gfp* line, (*TgBAC (tnfa:GFP)^pd1028^*) has been previously described ([@bib42]). The transgenic line *Tg(mfap4:GCaMP6F)^xt25^* was made by injecting Tol2 transposase mRNA and *tol2*-containing DNA constructs into zebrafish embryos at the one cell stage. The constructs were assembled with Tol2kit reagents and subsequent Gateway Cloning (Invitrogen) ([@bib35]). The 5' element containing the *mfap4* promoter, has been previously described ([@bib76]). The middle element GCaMP6F was generated by PCR amplification of the *GCaMP6F* coding region from the Addgene plasmid \#40755 using primers containing attB1 and attB2 sites followed by recombination into pDONR221. The 3' element was SV40polA in pDONR P2R-P3. The destination vector utilized was pDestTol2pA.

Generation of zebrafish lines possessing *p2rx7* loss-of-function alleles {#s4-3}
-------------------------------------------------------------------------

Loss-of-function alleles of *p2rx7* were generated by targeting the sequence 5'- GGTTTGATGTGATGGTGTTTGG-3' in exon 10 using CRISPR/Cas9 genome editing. The gRNA in vitro transcription template was generated as described previously ([@bib31]). Briefly, single-stranded DNA oligos 5'-GGTTTGATGTGATGGTGTT-3' and 5'-AAACAAACACCATCACATCAA-3' were annealed and inserted into the T7cas9sgRNA2 vector ([@bib31]). The resulting plasmid was linearized with BamHI (New England Biolabs R0136S), purified, and 400 ng was used as a template for in vitro transcription using the T7 MEGAshortscript kit (ThermoFisher AM1354). gRNAs were co-injected with Cas9 mRNA into single cell \*AB, wildtype embryos. CRISPR/Cas9-mediated mutations were determined by HRMA (described below) and Sanger sequencing. Two alleles were maintained: a five base pair deletion *p2rx7^xt26^*and a T to A transversion with a two base pair deletion, *p2rx7^xt28^*. Both mutations cause a premature stop codon in exon 10 ([Figure 3A--B](#fig3){ref-type="fig"}). The *p2rx7* mutant lines were crossed into *Tg(mfap4:GCaMP6F)^xt25^*, *Tg(mfap4:tdTomato)^xt12^*, and *Tg(mfap4:tdTomato-CAAX)^xt6^* and subsequently homozygosed in each transgenic background. Homozygous *p2rx7* mutants were viable and exhibited no apparent anatomical or fertility defects. *asc/pycard* loss-of-function alleles were generated by TALEN-mediated targeting ([@bib15]) of *pycard* exon 1, resulting in a 14 base pair deletion in the PYRIN domain ([Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). *pycard* mutant animals are viable as adults and of similar size and fecundity.

Characterization and maintenance of *cmaA2* transposon mutant *M. marinum* {#s4-4}
--------------------------------------------------------------------------

### Identification of transposon insertion sites {#s4-4-1}

Two transposon mutants with disruptions in the *cmaA2* ORF, designated *cmaA2^Tn01901^* and *cmaA2^Tn02791^*, were identified from a sequenced library of *M. marinum* transposon mutants (C. Cosma and L. Ramakrishnan). The previously identified insertion sites were confirmed by semi-random PCR and sequencing, using a pool of semi-random primers in conjunction with a pair of nested primers annealing within the 3' end of the transposon. Primer sequences are as follows: Semi-random pool: 5'-GCAACNNNNGTCTCGTTAGCTCGCTGGCC-3'; 5'-ATATCNNNNGTCTCGTTAGCTCGCTGGCC-3'; and 5'-GTACTNNNNGTCTCGTTAGCTCGCTGGCC-3', where N denotes random nucleotide insertion during primer synthesis (Integrated DNA Technologies). Outer transposon-specific primer (TnMarR3): 5'-ACAACAAAGCTCTCACCAACCGTG-3'; Inner transposon-specific primer (TnMarR2): 5'-CAGACACTGCTTGTCCGATATTTGATTTAGG-3'.

The semi-random primer pool and TnMarR3 were used to perform an initial, unbiased amplification of a region around any possible transposon insertion junctions. A second amplification was then performed using a primer corresponding to the constant region of the semi-random pool (5'-GTCTCGTTAGCTCGCTGGCC-3') and TnMarR2. The product of the second amplification was sequenced using TnMarR2, and the output was aligned to the *M. marinum* genome (BLASTn, NIH). The presence of a single sequence aligning to the *cmaA2* locus confirmed the presence of only a single transposon insertion in each genome and disruption of the *cmaA2* ORF for both *cmaA2^Tn01901^* and *cmaA2^Tn02791^*. The insertion site for *cmaA2^Tn01901^* is located \~ 14% into the ORF between the first and second bases of the 42^nd^ codon. The insertion site for *cmaA2^Tn01901^* is located \~ 75% into the ORF between the second and third bases of the 230^th^ codon. *CmaA2^Tn01901^* (Tn01901) was selected for further study.

Generation of fluorescent transposon mutant strains {#s4-5}
---------------------------------------------------

The mutants possess the TnMar transposon, conferring resistance to Hygromycin B. Fluorescent strains were generated by electroporating (800 Ω, 25 μF, 2.5 kV, 0.2 cm gap) msp12:mCerulean-KanR (a gift from L. Ramakrishnan, University of Cambridge) into either mutant strain. Selection on media containing Kanamycin (20 μg/ml) and Hygromycin B (50 μg/ml) yielded mutant clones expressing the mCerulean fluorescent protein.

Bacterial preparations {#s4-6}
----------------------

Wild-type *Mycobacterium marinum* (*M. marinum*) constitutively expressing a fluorescent protein (tdTomato, mCerulean, or Wasabi) and a Hygromycin resistance cassette driven by the *msp12* promoter were grown to late log phase (OD~600~ = 0.8) at 33°C in liquid 7H9 complete media (Middlebrook 7H9 base, Difco BD 271310) supplemented to a final concentration of 10% OADC (50 g/L BSA, 0.5% oleic acid, 20 g/L dextrose, 8.5 g/L NaCl), 0.05% Tween-80 (Fisher BP338-500), and 50 ug/mL Hygromycin B (Sigma H0654). *M. marinum* ΔRD1 was a gift from Lalita Ramakrishnan ([@bib75]). Bacteria were prepared into single-cell suspensions, as described ([@bib70]). Single-cell suspension aliquots were diluted to approximately 1 × 10^8^ cfu/mL in 5 μL 7H9 media + OADC and were stored at −80°C long-term and diluted in 7H9 to an appropriate concentration prior to injection.

Bacterial broth growth assay {#s4-7}
----------------------------

Wild-type *M. marinum* expressing tdTomato was grown to OD~600~ = 0.8 and then diluted 1:10 in 7H9 complete media supplemented with 50 ug/mL Hygromycin B in 15 mL culture tubes (Falcon). The bacterial culture was supplemented with 0.5% DMSO (MPI), 200 µg/mL Isoniazid (Sigma-Aldrich I3377), 10 µg/mL moxifloxacin (Matrix Scientific 047902) or 5 µM of each chemical and grown in a 33°C shaker for 7--8 days. Each day, 100 µL of the broth was placed in a cell culture 96-well microplate plate (GBO 655090) and analyzed with an Enspire 2300 Multilabel Plate Reader (PerkinElmer) for OD~600~ and fluorescence intensity, with three technical replicates per sample. The same methods were used for a growth curve in the presence of clemastine (Sigma, SML0445) for both *M. marinum* expressing mCerulean and *M. marinum* ΔRD1 expressing tdTomato (data not shown).

Larval zebrafish infection {#s4-8}
--------------------------

Two dpf larvae were anaesthetized with tricaine (MS-222; Sigma-Aldrich 160 μg/ml) and injected with fluorescent *M. marinum*. Single-cell suspension aliquots are diluted in 7H9 with 0.5% phenol red indicator (Sigma 0290) prior to injection. Between 50 and 200 CFU of fluorescent *M. marinum* were injected using a borosilicate needle (Sutter Instruments BF100-58-10), pulled with a WPI PUL-1000 system (factor setting 0) and broken approximately 8 mm from the tip. Injections are performed using a FemtoJet injector (Eppendorf). After infection, larvae were recovered in E3 +PTU for 4 hr at 28°C. For examination of mutant phenotypes, infections were performed blind to larval genotype.

Drug treatments {#s4-9}
---------------

Four hours post-infection, larvae were transferred to wells containing E3 + PTU supplemented with the compound being tested. For most studies, larvae were kept in six-well plates (COSTAR 3736) containing E3 + PTU supplemented with either 0.5% DMSO (MP Bio CAS 67-68-5) or 5 μM clemastine fumarate (Sigma-Aldrich SML0445) dissolved in 100% DMSO to a final concentration of 0.5% DMSO in each treatment group. Diphenhydramine hydrochloride (Sigma-Aldrich D3630) was dissolved in 100% DMSO and diluted to a final concentration of 5 μM. All drugs were added directly to E3 + PTU. Whenever agarose was used to mount fish, the same concentration of drug was added to the agarose prior to solidification.

Live imaging and quantification of bacterial burden {#s4-10}
---------------------------------------------------

Epifluorescence microscopy was carried out on an inverted Zeiss Observer Z1 microscope using 2.5X, 5X, or 20X objectives, depending on experiment. Prior to imaging, larvae were anaesthetized with tricaine (160 μg/ml) and arrayed on a microscope slide or embedded in 0.75% low melting point agarose (Fisher BP165) in a 35 mm petri dish (MatTek). Bacterial burden by fluorescence is calculated using ImageJ ([@bib61]). Images are analyzed for the mean fluorescence and area of fluorescence above a threshold within the zebrafish. The threshold is empirically determined for each experiment to ensure that every infected animal has a non-zero value while not including any background autofluorescence. The threshold is kept constant between treatments within an experiment. The product of the mean fluorescence and area is computed and presented as 'Mm Fluorescence.' Granuloma explants were visualized on a spinning disk confocal (Andor) using 10x/0.3 UPlanFl N dry, WD: 10 mm, FN26.5, UIS2 objective, acquiring images with an Andor Ixon3 897 512 EMCCD, 1.2x auxilary magnification camera. Z stacks were taken at 10--15 μm, and images are assembled as maximum intensity projections using ImageJ ([@bib61]). During image analysis, experimenter was blinded to the genotype of the larvae.

Light-sheet microscopy {#s4-11}
----------------------

Light-sheet fluorescence microscopy experiments were carried out on a Zeiss Light-sheet Z.1 using a Plan-Apochromat 20X/1.0 NA Aqueous immersion objective, situated with a C.mos PCO.edge camera with 16bit 1920 × 1920 sensors. One track, emission selection: 488/498 (GFP) and 560/571 (tdTomato). Light-sheet thickness was 4.32 microns with a continuous drive, 1x zoom, dual side illumination. For these experiments, two dpf zebrafish larvae *Tg(mfap4:GCaMP6F)^xt25^* and *p2rx7^xt26^;Tg(mfap4:GCaMP6F)^xt25^* were infected as described and treated with DMSO or clemastine at four hpi. One to 2 hr post-treatment, larvae were placed in 1.5% low-melting point agarose, supplemented with 80 μg/ml tricaine and either 0.5% DMSO or 5 µM clemastine fumarate (Sigma-Aldrich SML0445) in a 3 mm OD glass capillary. A dual-colored z-stack was acquired every 8.8 s, collecting 80 z-steps, using a z-step size of 1 μm for 30 min.

Light-sheet videos were projected as maximum intensities and analyzed using ImageJ ([@bib61]). Regions of interest (ROIs) were defined as single macrophages that expressed baseline levels of green fluorescence by GCaMP6 and flashed at least once over the course of the video. Macrophages outside of the caudal hematopoietic tissue were excluded. Only individual flashes were counted, not coordinated flashes during which every macrophage, infected and uninfected, underwent a calcium flash simultaneously. If the macrophage was not in frame for the entire 30 min, it was not included in the analysis. Quantitative analyses of macrophage calcium flashes were performed blind to the treatment type and genetic identity of the specimens under observation.

Adult infections and granuloma explants {#s4-12}
---------------------------------------

Adult zebrafish (\>2 months old) were infected as described ([@bib53]). Briefly, adult fish (\>2 months old) were anesthetized by immersion in 100 μg/mL tricaine and injected intraperitoneally with 300 CFU of *Mm:mCerulean* or *Mm:tdTomato* using insulin needles (BD 08290-3284-38). Adult fish were kept in 1L tanks in a dedicated infection incubator with light/dark cycles at 28°C, with water changes and feeding every day. Between two and four weeks post-infection, granulomas were harvested using a Myco-GEM method ([@bib14]). Briefly, after adult fish are euthanized with a lethal dose of tricaine, the body cavity is exposed in sterile L15 medium (Gibco 21083--027). Granulomas can be dissected out with forceps or gently removed by a glass pipette. Granulomas are serially washed in sterile L15 and size-matched for treatment groups. The bottom of an optical-bottom 96-well plate (GBO 55090) is covered with 40 μL of 5 μg/mL Matrigel Matrix (Corning 354262), in L15. Granulomas are embedded in 2.5-dimensional top media with a final concentration of 5% FBS (Sigma 2442), and 1 μg/mL Matrigel matrix (Corning 354262) in L15 (Gibco 21083--027) as described ([@bib14]). The top and bottom media are supplemented with either DMSO (0.5%) or clemastine (5 μM in 0.5% DMSO). Granulomas are imaged via microscopy at d0 and 5 days post-treatment (dpt) using epifluorescence microscopy on an inverted Zeiss Observer Z1 microscope and on a spinning disk confocal (Andor). *M. marinum:Lux* granulomas were imaged daily as described below. Image acquisition and analyses were performed blind to the genotype of the granulomas.

Bioluminescence assay {#s4-13}
---------------------

For this assay, we used a bioluminescent reporter strain of *M. marinum* (*Mm*-Lux) as described in [@bib14]. Adult zebrafish were infected as described above and granuloma explants cultured in the same methods as described above but were kept in white 96-well cell culture microplates (GBO 675098) and luminescence was determined using an EnSpire 2300 Multilabel Plate Reader obtained from Perkin Elmer (Waltham, MA). Drug treatments were applied in the same fashion as fluorescence assays, with drug added to both bottom media and top media.

Flow cytometry and FLICA staining of granuloma explants {#s4-14}
-------------------------------------------------------

For all flow cytometry experiments, we cultured granuloma explants as described above for 48 hr in the presence of 0.5% DMSO or 5 µM clemastine. Granulomas were rinsed in sterile L15 and PBS. Following manufacturer's directions, 660-FLICA Caspase Assay (Immunochemistry Technologies ICT097) was reconstituted with 50 µL 100% DMSO to make 150X stock. This stock was aliquoted into single use tubes and kept at −20°C and not freeze-thawed more than once. Just prior to use, the 150X stock was diluted 1:5 in PBS to make 30X stock. Grouped granulomas (\~10 per group) were placed in 1.5 mL tubes with 97 µL PBS and 3 µL of 30 × 660 FLICA stock. Granulomas were kept at 28°C for 1 hr. Granulomas were washed in 1X apoptosis buffer and spun at 1200xg for 1 min three times. Granulomas were resuspended in 1 mL 0.05% trypsin in 1X EDTA (ThermoFisher Scientific, 25300) and kept on a nutator for 40 min at 30°C. Granulomas were centrifuged for 5 min at 300xg and rinsed with 1 mL 5% FBS in PBS three times, gently pipetting off supernatant each time, resuspended in 300 µL 5%FBS in PBS and pipetted over a 30 µm cell strainer (MACS Miltenyi 130-098-458). Single cell suspensions were analyzed on a FACS Canto II (BD Biosciences) using an Apc-Cy7 laser (633 nm) excitation. Data was collected using FACSDiva Software (BD Biosciences) and analyzed using FlowJo v10 (Treestar).

Colony-forming unit (CFU) assay on granuloma explants {#s4-15}
-----------------------------------------------------

Granulomas were cultured as described above for up to a week. On the final day of treatment, individual granulomas were washed in sterile PBS, as in [@bib14]. Briefly, individual granulomas were homogenized in sterile 7H9 media in a microcentrifuge tube with two sterile glass beads. Homogenates were diluted incrementally to 10^−6^ and plated on 7H10 media (BD Difco 262710) supplemented with 20 µg/mL kanamycin (Sigma-Aldrich K0129). Plates were incubated for 12--14 days at 30°C.

Prestwick chemical library screen {#s4-16}
---------------------------------

The Prestwick Chemical Library (Prestwick Chemical, Illkirch, France) was stored at −80°C at 10 mM and aliquoted manually into 1 mM working stock daughter plates in 100% DMSO. The daughter plates were stored at −20°C until used in 96-well format. Wildtype zebrafish larvae carrying a TNF reporter transgene (*Tg(BAC(tnfa:GFP)^pd1028^*) ([@bib42]) were arrayed in 96-well optical plates (GBO 655090) with three infected and one uninfected fish per well, in 200 µL of E3 + PTU and 5 µM of each chemical. First and last rows of each plate were maintained as 0.5% DMSO controls. Each plate contained 80 drugs, with 15 plates in all. Burden was assayed by fluorescence area and mean intensity of fluorescent mycobacteria at five dpi. In the secondary screen, hits were screened again in the same format (three infected fish, one uninfected fish) and drugs that continued to reduce bacterial fluorescence area and mean intensity were tested again in a tertiary screen with 20 fish per group, with DMSO-treated fish as control.

Determination of relative *M. marinum* burden by 16S rRNA qRT-PCR {#s4-17}
-----------------------------------------------------------------

Total RNA was isolated from each group of larvae using TRIzol Reagent (Thermo Fisher Scientific 15596026). An input mass of 1 μg of RNA per group was used for cDNA synthesis using the iScript cDNA Synthesis Kit (Bio-Rad 1708890). Average relative bacterial burdens were quantified by qPCR (Power SYBR Green PCR Master Mix, Thermo Fisher Scientific 4368577) targeting the *M. marinum* 16S locus. F primer: 5'-CGATCTGCCCTGCACTTC-3'; R primer: 5'-CCACAGGACATGAATCCCGT-3'. Zebrafish β-actin transcript levels were used as the internal input control. F primer: 5'-CGAGCAGGAGATGGGAACC-3'; R primer: 5'-CAACGGAAACGCTCATTGC-3' ([@bib77]).

Genotyping assays {#s4-18}
-----------------

All genotyping assays were performed on fin-clips from adult zebrafish or post-experiment on whole larval animals, using genomic DNA isolated as described ([@bib45]). *p2rx7^xt26^* and *p2rx7^xt28^* were genotyped via KASP assays (LGC Genomics, Middlesex UK). *pycard^w216^* mutant larvae were genotyped using HRMA (Applied Biosystems MeltDoctor HRM 4415440). *irf8* mutations were genotyped using PCR amplification and AvaI restriction digest, as described ([@bib64]). Additionally, HRMA primers were developed to more rapidly genotype *irf8* mutant fish. All initial mutations were confirmed via Sanger sequencing.

Primer sequences are as follows: *pycard* HRMA primers:

5' AATCGAAAAGCTGAAAGACGAG 3'

5' ACTTACATTGCCCTGTGTTCCT 3'

*p2rx7* sequencing primers:

5' TGCGTGCCAAACATTACACTT 3'

5' AGACGTTGTGTGGGATGTGG 3'

*irf8* HRMA primers:

5' CGGCATACTAGTGAAGTAAAGG 3'

5' CTATAAGCCACTGTTTCAGT 3'

*irf8* sequencing primers:

5' ACATAAGGCGTAGAGATTGGACG 3'

5' GAAACATAGTGCGGTCCTCATCC 3'

Statistical analysis {#s4-19}
--------------------

All statistics were performed using Prism (GraphPad), version 7. Statistics presented are performed on data presented for each graph (e.g. if a graph displays y=log~10~(y) transformation, then the p values are from a statistical test on that data). All p values from statistical tests performed on transformed and untransformed data are provided in [Supplementary files 2](#supp2){ref-type="supplementary-material"} and [3](#supp3){ref-type="supplementary-material"}.
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###### Summary of identified compounds.

Compounds with blue background are host directed and compounds in red are known anti-infectives. Asterisk (\*) represents compounds with previously identified host-directed anti-mycobacterial activities.
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###### Summary of p values and statistical tests for [Figures 1](#fig1){ref-type="fig"}--[6](#fig6){ref-type="fig"}.

Statistics performed on transformed data are in yellow and untransformed is in gray. The table is organized by figure number, in chronological order. Statistical tests are listed and transformation equation provided, where applicable. When a paired t-test is performed on paired data, the results of the unpaired t-test are also given. When both paired and unpaired are potentially appropriate (in the case of paired data with ineffective pairing), both test results are given. Statistical test results in *italics* denote tests not presented within the figures.
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###### Summary of p values and statistical tests for the figure supplements to Figures 1-6.

Statistics performed on transformed data are in orange and untransformed is in light blue. The table is organized by figure number, in chronological order. Statistical tests are listed and transformation equation provided, where applicable. When a paired t-test is performed on paired data, the results of the unpaired t-test are also given. When both paired and unpaired are potentially appropriate (in the case of paired data with ineffective pairing), both test results are given. Statistical test results in *italics* denote tests not presented within the figure.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for submitting your work entitled \"Potentiation of P2RX7 as a Host-Directed Strategy for Control of Mycobacterial Infection\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Amy Barczak (Reviewer \#4).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

Reviewers generally expressed enthusiasm for the elegant study design and clear and logical presentation. They noted the novel and interesting in vivo imaging methods, applied in a creative way to assess host directed effects. There was also enthusiasm for attempts made to determine the mode of action for clemastine. However, there were several notable shortfalls that preclude publication in *eLife*. These include the relatively marginal effect of clemastine, lack of clarity regards statistical evaluation and significance, no attempts to correlate florescent readouts with CFUs, and notable weaknesses in the inflammasome activation component of the study.

*Reviewer \#1:*

Summary:

In their submission, the authors describe a study that uses zebra fish, at the transparent larval stage, to search for new host directed therapies (HDTs) for tuberculosis. They start by screening 1200 FDA approved drugs in a survival assay, with Mycobacterium marinum-infected in zebra fish, with a reduction in bacterial load as the measured outcome, and identify 23 promising candidates for further study. They focus on a subset of compounds that have host-directed activity rather than direct bactericidal activity per se and settle on further characterising clemastine, as it is inexpensive and widely available. The authors demonstrate that during infection with *M. marinum* in zebra fish, clemastine was able to reduce bacterial burdens in infect larvae in a dose-dependent manner. Given that this compound had no demonstrable antibacterial activity, this clearance was attributed the host-directed effects of clemastine. To further probe what aspect of host metabolism this drug disturbed, the authors treated infected larvae that lack macrophages, using an *irf8* mutant that is unable to generate macrophages. In this case, bacterial burdens were higher and clemastine had no effect, suggesting that clemastine targeted macrophage function. To dissect these effects in vivo, the authors conducted imaging of infected zebrafish where macrophages and bacteria were labelled with differentiating colours and demonstrate that clemastine reduced the intra-macrophage bacterial load. Next, the authors probe whether clemastine affects phagosome acidification and report no significant difference in acidification upon clemastine treatment. To further study the effects of clemastine on host cells, the authors assess its effect on the P2RX7 receptor. They generate mutant larvae defective for domains of this receptor and combine this with a calcium reporter, followed by the use of light sheet microscopy to study real-time calcium dynamics in vivo. Using this approach, the authors demonstrate that clemastine treatment results in an increase of calcium flashes, an effect that was abrogated in P2RX7 mutants. Consistent with this, clemastine had negligible activity in P2RX7 mutants, an observation further augmented with experiment using a P2RX7 inhibitor. Following these observations, the authors then assess the effect of clemastine on inflammasome activation by using an RD1 mutant of *M. marinum*, that lacks the specialized secretion apparatus required for mycobacterial interaction with host inflammation pathways. Clemastine had no effect in this case. To further probe inflammasome activation, the authors use a mutant defective in Asc, the adaptor required for inflammasome activation, and clemastine was ineffective in this background. Finally, the authors demonstrate that clemastine is effective in mature granuloma explants from adult zebrafish. This is a well-executed, clearly presented study. Some points detract; these are given below.

Essential revisions:

1\) Videos require some detailed annotation and processing to outline the larvae and point out the bacteria, sometimes it\'s hard to figure out what is happening. More detailed legends would be useful. The stills in the Supplementary information do help, but without these the videos are not really useful and perhaps should be replaced by a series of more closely spliced still images. This is especially applicable with the calcium flashes, where it is harder to compare the rates of flashing to the control. Some thought should be given to this. Perhaps creating a composite movie of the control and clemastine treated fish side-by-side would be useful?

2\) Confirmation of the various mutants generated in zebrafish seems to be missing; either Southern blot or Western blots indicating that protein domains were removed. Some form of confirmation should be provided.

3\) A model that pulls all the observations together will enhance the readability of the manuscript.

*Reviewer \#2:*

In this very elegant study, Matty et al. use the *M. marinum* / zebrafish model as an in vivo screening tool to identify host-directed FDA approved drugs that affect intracellular mycobacterial growth. After counter-screening pathogen-targeting molecules, they select and confirm Clemastine as the most potent host-directed candidate, and go on to decipher its mechanism of action, showing that macrophages are required, and that clemastine acts as an agonist of the P2RX7 receptor leading to increased intracellular calcium flashes which in turn activate the inflammasome known to control bacterial growth. The manuscript is very clearly written, the research strategy follows a logical flow and the experiments are thoroughly executed; the concern mostly lies in the size of the clemastine effect. Review by a statistics expert is recommended.

Essential revisions:

In the initial screen, it is somewhat surprising that several drug classes known to be active against *M. marinum* (https://doi.org/10.1186/s12941-016-0145-1) didn\'t emerge as primary hits: rifamycins, aminoglycosides, macrolides, trimethoprim. Could the authors comment on this?

Why use INH at a very high concentration (200 ug/mL) as a positive control since it as little to no activity against non-TB mycobacteria given that it\'s a prodrug requiring intrabacterial activation? There are many more potent alternatives, see above.

The size of the clemastine-mediated effect is rather small (two-fold effect at most across assays, conditions and experiments), triggering a few questions as to the read-outs and statistical analyses.

\- How do fluorescence units relate to bacterial burden in zebrafish? Has this been calibrated? Could the authors explain this in subsection *"*Live imaging and quantification of bacterial burden", beyond \"Bacterial burden is presented as the product of area and mean intensity of bacterial fluorescence.\"?

\- Were the non-transformed or log-transformed fluorescence values used in the statistical analyses? If the latter, could the author also include the p-values of the non-transformed data?

\- In some experiments, the differences between what is declared as statistically significant and what isn\'t are subtle. This is best illustrated by Figure 2B and 2F where the visual impression doesn\'t clearly convey the message. While the burden is higher in macrophage-free zebrafish, the clemastine effect or lack thereof can\'t be assessed from these images.

In the Discussion section, could the authors mention and comment on the recent paper by Mawatwal et al., (2017): \"Calcimycin mediates mycobacterial killing by inducing intracellular calcium-regulated autophagy in a P2RX7 dependent manner\". What are the implications of their findings in the context of this study?

Reviewer \#3:

In this manuscript the authors describe an in vivo whole animal screen of 1200 FDA-approved drugs to identify novel host-directed therapeutics with activity against mycobacteria. They identify clemastine as a drug that restricts replication of the zebrafish pathogen Mycobacterium marinum in vivo (but not in broth). Although clemastine is better known as an anti-histamine, the efficacy of the drug in vivo is proposed to be due to \'off-target\' agonism of the fish P2RX7 ion channel that results in a protective response involving activation of a host immune \'inflammasome\' pathway.

There are several nice aspects to the work. The manuscript is well written, and the data are logically and clearly presented. To my knowledge, this is the first in vivo screen for anti-mycobacterial drugs. This is significant because compounds with in vitro efficacy often fail in vivo. In addition, the authors also take advantage of the optical transparency of zebrafish embryos to perform some nice imaging analyses of infected animals, particularly the calcium flux experiments in Figure 3.

Despite these positive aspects, I have two major reservations about the potential impact of the work: (1) the effects observed are small and some of the statistical interpretations are problematic (see below); and (2) although the authors propose their observations are relevant to human tuberculosis, I do not find this sufficiently convincing in the absence of experiments with the actual human pathogen (*M. tuberculosis*) in mammals with lungs and adaptive immunity (which is absent in the embryos used here). In addition, mammalian/*Mtb* models often use survival or at least animal health as an endpoint \'gold standard\', whereas only bacterial burdens are shown in the present manuscript. Because I suspect there will be some sensitivity with respect to this point, I should be clear that I am not saying the zebrafish is a poor model for *M. tuberculosis* lung infections; it may or may not be, and whether it is or not likely differs in different scenarios. I am merely saying that the relevance has not been established in this specific case, and this is a problem because such relevance is one of the authors\' major claims for the significance of their work.

Essential revisions:

1\) The magnitude of the effects of clemastine are very modest and appears to vary from experiment to experiment. The effect in Figure 2 is said to be approximately \~60% reduction (i.e., \~2-fold), but in other experiments (e.g., Figure 5A,B, Figure 6B, etc.), the effect appears to be even less. Obviously, there is no objective threshold that determines when the magnitude of a biological effect is sufficiently large for a journal such as *eLife*. It is a judgment call; and this reviewer\'s judgment is the magnitude of the effects will affect the impact of this work.

2\) I am having trouble with the way statistics are used to support some of the main claims of the paper. My trouble relates to the difference between showing an observed difference is not significant versus showing that there is no difference. For example, in Figure 4, the authors seek to establish one of the main claims of the paper, namely that the effect of clemastine on bacterial burden is p2rx7 dependent. In fact, I believe what is shown is that there is no evidence that the drug has an effect in p2rx7 knockouts, which is quite a different thing (and could in fact be claimed even if no experiment had been done at all). Indeed, it appears to me that there may be an effect of the drug in p2rx7-deficient animals, even if the difference didn\'t reach a similar degree of statistical significance as in WT (perhaps due to the lower n?). Instead of reporting that there is no statistically significant effect of the drug in p2rx7 knockouts, I think it would be preferable to arrange the statistical testing in such a way that it is possible to conclude that the effect of the drug (fold restriction of bacterial burdens?) is statistically different in WT vs p2rx7 knockouts. In addition, is the Clemastine+P2RX7+ group significantly different than the Clemastine+P2RX7- group?

*Reviewer \#4:*

In this work, Matty et al. use a zebrafish model of *M. marinum* infection to screen a bioactive library of small molecules to identify novel host-directed anti-mycobacterial agents. This work is novel in that it represents the first whole organism screening approach to identifying novel anti-TB therapies, and successfully identifies a drug in clinical use for other indications that has not previously been identified as restricting mycobacterial growth. Although antimycobacterial activity is not likely through its primary annotated target, the authors then identify a probable target and perform genetic studies to validate the target. The interpretation of the RD1 experiment results and presumed link between RD1 and the inflammasome is less convincing, with concerns as detailed below. The inclusion of the ex vivo granuloma model to evaluate longer term drug efficacy is both interesting and novel. Overall the study is well executed and in my opinion merits publication.

Essential revisions:

1\) RD1 data and link to the inflammasome: The authors show that clemastine does not further restrict the growth of an RD1 mutant, which lacks ESX-1 and thus fails to permeabilize the phagosome. This is interpreted as demonstrating that the drug only has efficacy if the bacterium has access to cytosolic contents, which is then used to justify thinking about how the inflammasome might be involved. I think this is problematic on two fronts: (1) An attenuated mutant (the RD1 mutant) might not be further growth-restricted by a host-directed drug for many reasons other than cytosolic access. I think (at minimum) testing the effect of clemastine against an attenuated mutant still able to access the cytosol would be necessary to begin to make that interpretation (2) The logical bridge between the requirement for cytosolic access and inflammasome activation is a weak one. The literature is divided on whether ESX-1 (i.e. cytosolic access of the bacterium) is required for activation of the two inflammasomes shown to be relevant in TB- AIM2 and NLRP3. While older literature suggested that activation of NLRP3 required ESX-1, the paper (PMID: 26048138) that best dissected out the relative contributions of NLRP3 and AIM2 to the overall inflammasome response to TB found that while ESX-1 was required for AIM2 activation, it was not required for NLRP3 activation. Further, permeabilizing the phagosome is known to be required for triggering other pathways, among other effects- to me, even though the ASC mutant data shows clemastine has no effect, there are logical gaps in getting to that experiment. I think the paper would be logically stronger if the RD1 and inflammasome data were removed.

2\) Lack of testing in combination with an established anti-mycobacterial drug: Host acting agents have relatively weak activity against *Mtb* when compared with standard antibiotics and will likely have to be used as adjuncts to other therapeutics. In some cases, drugs with activity against *Mtb* in host cells when used alone have been shown to compromise the activity of standard antibacterial agents when used in combination. An argument can be made that the standard for testing potential novel host-directed agents should include testing together with more standard antibiotics. If this type of model were not already established in the lab, these experiments would potentially go beyond 60 days - in which case I would still support publication of the manuscript without those experiments but would suggest that the potential for different effects in combination/need to test in combinations be addressed in the Discussion section.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for choosing to send your work entitled \"Potentiation of P2RX7 as a Host-Directed Strategy for Control of Mycobacterial Infection\" for consideration at *eLife*. Your letter of appeal has been considered by a Senior Editor and a Reviewing editor, and we are prepared to consider a revised submission with no guarantees of acceptance.

In preparing your revision, we would like to draw your attention to some important points for consideration.

1\) In the absence of rigorous statistical analysis, or the lack of a clear explanation as to how statistics were conducted, small (or even large) changes in a biological system are difficult to contextualize. We encourage you to consider this carefully in your data analysis. Regards statistics, pay particular attention to the correct choice of test to use, usually determined by the nature of the data, parametric versus non-parametric etc. Report these consistently in all figures, provide p-values for all comparisons (include the choice of test each time) and if necessary, include an expanded data analysis section in the Materials and methods section.

2\) Consider more carefully how you would incorporate inflammasome activation as the mechanism into your revision. Reviewers raised several concerns regards the RD1 mutant. However, simply removing it from the study may weaken the mechanism. We encourage you to think further as to how you can address this concern.

3\) We would like to affirm your sentiment that *eLife* values model systems as central to the scholastic pursuit of holistically understanding biological systems. The zebrafish model is no different in this case. However, it falls upon the authors to ensure that data presented in any manuscript are interpreted within the context of said model and not over-extended to humans or any other system without substantiating experiments. Please consider this carefully when preparing your revision and limit the interpretation to the model system that you are using, unless you have supporting/validation data from other systems.

10.7554/eLife.39123.028

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#1:
>
> Summary:
>
> In their submission, the authors describe a study that uses zebra fish, at the transparent larval stage, to search for new host directed therapies (HDTs) for tuberculosis. \[...\] This is a well-executed, clearly presented study. Some points detract; these are given below.
>
> Essential revisions:
>
> 1\) Videos require some detailed annotation and processing to outline the larvae and point out the bacteria, sometimes it\'s hard to figure out what is happening. More detailed legends would be useful. The stills in the supplementary information do help, but without these the videos are not really useful and perhaps should be replaced by a series of more closely spliced still images. This is especially applicable with the calcium flashes, where it is harder to compare the rates of flashing to the control. Some thought should be given to this. Perhaps creating a composite movie of the control and clemastine treated fish side-by-side would be useful?

We appreciate the reviewers' concern with the videos in their previous form. To address this concern, we have provided each control and clemastine treatment video set as a split screen movie. We hope that the additional clarification in Video 1 (previously Video 1 and Video 2) shows more clearly that clemastine-treated macrophages display microbicidal activity, and we have added tracking of individual bacteria, marked at the end of the movie with solid or outlined arrowheads, to represent still-present or disappearing bacteria within individual macrophages.

For the calcium transients and this analysis, which appeared most difficult to discern, we have revamped the presentation in the videos. Video 3 and Video 4 (now Video 2) have been recreated as a split screen video to show that the wildtype and p2rx7 mutant calcium signaling is similar in uninfected animals at baseline, with frame-by-frame annotations for each flash counted. For the calcium video of infected animals (Video 3 and Video 4, previously Videos 5-8), we have also circled or boxed the regions of interest (ROIs) for the infected cells, which were counted for the number of calcium flashes in that cell during the course of the video. The boxes appear when the cell flashes and they are color coded: if a cell flashes only once, its box will be yellow and if a cell flashes more than once, the box will be the same color throughout the video. More detailed legends are also provided with these newly combined and annotated videos.

> 2\) Confirmation of the various mutants generated in zebrafish seems to be missing; either Southern blot or Western blots indicating that protein domains were removed. Some form of confirmation should be provided.

We performed unambiguous Sanger sequencing as a confirmation of each deletion allele (Figure 3B and Figure 5---figure supplement 2A). Antibodies are not readily available for zebrafish P2rx7 and we were unable to find an antibody raised against mammalian P2RX7 that would cross react with zebrafish P2rx7. We regret that we cannot address this issue fully given the technology available to us but hope that the two distinct alleles each with the same phenotype suffice.

> 3\) A model that pulls all the observations together will enhance the readability of the manuscript.

We agreed that a model would enhance the readability of the manuscript. A model has been provided as Figure 7, with a succinct summary of the findings of our work.

> Reviewer \#2:
>
> \[...\] Essential revisions:
>
> In the initial screen, it is somewhat surprising that several drug classes known to be active against M. marinum (https://doi.org/10.1186/s12941-016-0145-1) didn\'t emerge as primary hits: rifamycins, aminoglycosides, macrolides, trimethoprim. Could the authors comment on this?

We have included a sentence to comment on this point within the manuscript (Introduction). Briefly, the concentration at which the screen was performed (5 µM) is much lower than the concentration at which these drugs have been shown to have effects in zebrafish, perhaps due to permeability issues (Adams et al., 2011). Indeed, we note as part of the new antibiotic plus clemastine experiments in Figure 6 that the in vivo MIC of a drug like moxifloxacin is substantially higher in the zebrafish model than its in vitro MIC.

> Why use INH at a very high concentration (200 ug/mL) as a positive control since it as little to no activity against non-TB mycobacteria given that it\'s a prodrug requiring intrabacterial activation? There are many more potent alternatives, see above.

This is an excellent point, and the concentration required for INH to be effective against *M. marinum* is unusually high and so it was a poor initial choice of control for lack of growth. Therefore, we have included an additional bacterial growth curve to address this, in which we use moxifloxacin at a concentration of 10 µg/mL as a positive control (Figure 6---figure supplement 3B). We also use moxifloxacin in additional new experiments with the granuloma model.

> The size of the clemastine-mediated effect is rather small (two-fold effect at most across assays, conditions and experiments), triggering a few questions as to the read-outs and statistical analyses.

We point out above that within our model -- a slow growing mycobacterium over the five-day infection possible in the zebrafish larva -- this represents a fairly large and robust effect size. It is on a par with effect sizes described for host perturbations in a number of other zebrafish-mycobacterium papers over the past 15 years. However, we appreciate this point and, in the course of performing additional experiments, found even larger effects in the adult granuloma explant experiments, as documented in the revised Figure 6.

We examined burden in the adult granuloma explant model using a variety of assays: fluorescence readout; bioluminescent readout using a *M. marinum lux* strain that we constructed, and CFU plating.

Overall, in larvae and granuloma explants, the effect size of clemastine treatment was generally between 0.5 log~10~ and 1.4 log~10~, or between 3-fold and 27-fold in most experiments. We have also added 16S rRNA-based analysis to complement the fluorescence quantification. In larvae and adult granulomas, we found good concordance with fluorescence values. And CFU assays in the adult granuloma model showed consistent and robust effects of clemastine on mycobacterial burden.

Finally, to show that clemastine can be combined productively with antibiotics, we have included experiments in ex vivo granulomas in which co-treatment with clemastine makes an antibiotic more effective (Figure 6F). We have also tried to clarify statistical analyses by providing more detailed descriptions of the analyses performed and the p-values presented therein.

*- How do fluorescence units relate to bacterial burden in zebrafish? Has this been calibrated? Could the authors explain this in subsection "*Live imaging and quantification of bacterial burden"*, beyond \"Bacterial burden is presented as the product of area and mean intensity of bacterial fluorescence."?*

Others have shown that fluorescence units of bacteria relate directly to CFU (Adams et al., 2011; Takaki et al., 2013; Walton et al., 2018). To further confirm these findings in our specific studies, we have also provided 16s rRNA qPCR analysis of key experiments, which directly corroborate the findings in fluorescence readouts in larvae (Figure 4---figure supplement 1C and Figure 4---figure supplement 2C and Results section). We have further confirmed that the fluorescence readouts in granuloma explant models represent bacterial burden by luminescence (Figure 6D, F and Figure 6---figure supplement 3A, C and Discussion section) and analysis of colony forming units (CFU) (Figure 6E and Materials and methods section). Because these experiments are technically challenging and terminal endpoints, qPCR and CFU are provided for confirmation of fluorescence and luminescence readouts. Bacterial burden by fluorescence is calculated using ImageJ. Images are analyzed for the mean fluorescence and area of fluorescence above a threshold within the zebrafish (as determined by brightfield imaging). This threshold is empirically determined for each experiment (to ensure that every infect animal has a non-zero value) and kept constant between treatments. The product of the mean fluorescence and area is computed and presented as "Mm Fluorescence". This was not clearly described the initial submission and has been added to the Materials and methods section.

> \- Were the non-transformed or log-transformed fluorescence values used in the statistical analyses? If the latter, could the author also include the p-values of the non-transformed data.

Due to the spread of the data, most bacterial data are presented as log~10~(Mm fluorescence) and statistics are performed on the data presented within each figure, i.e. if a figure shows transformed data, then the p-values shown are from the statistical tests on that data. We have provided statistics performed on both transformed and untransformed values in Supplementary file 2 and Supplementary file 3. In all experiments, the only circumstances under which transforming data changes the p-values are (1) when the variation among standard deviations changes, requiring a different statistical test correction, and (2) when there are values of '0' among the results, as log~10~(0) is undefined. However, after proper thresholding, there were no '0' 'Mm fluorescence' values as all animals had some degree of infection (see above).

> \- In some experiments, the differences between what is declared as statistically significant and what isn\'t are subtle. This is best illustrated by Figure 2B and 2F where the visual impression doesn\'t clearly convey the message. While the burden is higher in macrophage-free zebrafish, the clemastine effect or lack thereof can\'t be assessed from these images.

We agree that we should have done a better job presenting these images. The differences can appear subtle when showing the entire animal as an overlay of fluorescence and brightfield in a single two-dimensional image. We have now added arrowheads to mark the points of infection in each animal, so that the differences between clemastine-treated and control animals should be apparent. We have brightened the images in Figure 2F to contrast the bacteria and brightfield images. The brightening was performed equally as noted in the legend across the clemastine and DMSO-treated wildtype animals, is only for the purpose of better seeing the bacteria above the brightfield image and was not used for quantification. We think that bacterial burden and differences in the clemastine treated groups are now much more easily assessed. As noted within the figure legends, the animals that are used as example images are highlighted in the graph and are at or near the mean for the group.

> In the Discussion section, could the authors mention and comment on the recent paper by Mawatwal et al., (2017): \"Calcimycin mediates mycobacterial killing by inducing intracellular calcium-regulated autophagy in a P2RX7 dependent manner\". What are the implications of their findings in the context of this study?

Thank you for pointing out the possibility for autophagy to be a mechanism through which clemastine reduces bacterial burden in a calcium-dependent manner. We have added this reference to the Discussion section and Results section as an introduction to a new set of experiments. We have explored the role for clemastine in autophagy-induced killing of mycobacteria in multiple ways and have found that clemastine has no effect on autophagic flux, using a zebrafish line which labels LC-3 puncta with GFP (He et al., 2009). In this line, we observed the same number of GFP: LC-3 puncta decorating intracellular bacteria in DMSO and clemastine-treated animals (Figure 5---figure supplement 2D). We have also observed that clemastine is still effective in zebrafish lacking critical autophagy-related genes, including ATG5, ATG7, ATG12, and Beclin1 (data not shown because these zebrafish mutants were provided to us by collaborators to test but are not yet published). In this case, we think that clemastine's mechanism of action is independent of autophagy.

> Reviewer \#3:
>
> \[...\] Despite these positive aspects, I have two major reservations about the potential impact of the work: (1) the effects observed are small and some of the statistical interpretations are problematic (see below); and (2) although the authors propose their observations are relevant to human tuberculosis, I do not find this sufficiently convincing in the absence of experiments with the actual human pathogen (M. tuberculosis) in mammals with lungs and adaptive immunity (which is absent in the embryos used here). In addition, mammalian/Mtb models often use survival or at least animal health as an endpoint \'gold standard\', whereas only bacterial burdens are shown in the present manuscript. Because I suspect there will be some sensitivity with respect to this point, I should be clear that I am not saying the zebrafish is a poor model for M. tuberculosis lung infections; it may or may not be, and whether it is or not likely differs in different scenarios. I am merely saying that the relevance has not been established in this specific case, and this is a problem because such relevance is one of the authors\' major claims for the significance of their work.

We appreciate the reviewer's critique and enthusiasm for the novelty of the in vivo screen for anti-mycobacterial drugs that may be host directed. We have addressed the reviewer's two major reservations throughout.

1\) Effect size and statistical interpretations.

We point out above that within our model -- a slow growing mycobacterium over the five-day infection possible in the zebrafish larva -- this represents a fairly large and robust effect size for a host-directed monotherapy. It is on a par with effect sizes described for host perturbations in a number of other zebrafish-mycobacterium papers over the past 15 years, as well as host perturbations in other animal models. However, we appreciate this point. We note that, in the course of performing additional experiments for this revision, we confirmed the burden differences in a number of independent ways: 16S rRNA analysis; construction of a *lux* bioluminescent strain to measure burden in granuloma explants; and CFU measurement in treated granulomas. We noted even larger effects in the adult granuloma explant experiments as now measured by CFU and luminescence (median effect of 1.4 log~10~ reduction in burden over seven days relative to vehicle) as documented in the revised Figure 6.

We have also now included more robust statistical descriptions for the analyses we performed within the figure legends throughout, including, in supplementary data, adding parallel analysis of both log transformed and non-transformed data and providing two supplementary tables (Supplementary file 2 and Supplementary file 3) comprehensively documenting all p values throughout. We have also performed specific analyses requested by the reviewer, described below.

We have also added new experiments showing that clemastine can be used to enhance the effect of an antibiotic in the ex vivo granuloma model (Figure 6F and Figure 6---figure supplement 3C).

2\) Concerns about the zebrafish

We recognize and appreciate that our findings are within the context of an animal model of mycobacterial infection and have emphasized the new biological insights obtained using a natural host-pathogen pairing and a whole animal in vivo drug screen. We have restructured the Introduction and Discussion section to focus on those findings within this context, and while we do believe that animal models are useful in understanding conserved fundamental features of mycobacterial infection, have been careful to emphasize that our current findings are within this system.

> Essential revisions:
>
> 1\) The magnitude of the effects of clemastine are very modest and appears to vary from experiment to experiment. The effect in Figure 2 is said to be approximately \~60% reduction (i.e., \~2-fold), but in other experiments (e.g., Figure 5a, 5b, 6b, etc.), the effect appears to be even less. Obviously, there is no objective threshold that determines when the magnitude of a biological effect is sufficiently large for a journal such as eLife. It is a judgment call; and this reviewer\'s judgment is the magnitude of the effects will affect the impact of this work.

The effect is consistent and usually a 3-10 fold reduction (0.5 log~10~ to 1 log~10~) over a relatively short time period, as discussed above. To further support our findings, we have added additional methods to detect changes in bacterial burden. Specifically, we have used 16S rRNA qPCR analyses to confirm that clemastine reduces bacterial burden by an independent measure in larvae but fails to do so in *p2rx7* mutant animals (Figure 4---figure supplement 1C) and RD1 mutant bacteria (Figure 5---figure supplement 1C). Further, in new data from the granuloma explant model, clemastine's effect appears greater (median reduction of 1.4 log~10~ when measuring by CFU plating). In addition, we show similar results over seven days of treatment against infections using the new *lux* strain.

> 2\) I am having trouble with the way statistics are used to support some of the main claims of the paper. My trouble relates to the difference between showing an observed difference is not significant versus showing that there is no difference. For example, in figure 4, the authors seek to establish one of the main claims of the paper, namely that the effect of clemastine on bacterial burden is p2rx7 dependent. In fact, I believe what is shown is that there is no evidence that the drug has an effect in p2rx7 knockouts, which is quite a different thing (and could in fact be claimed even if no experiment had been done at all). Indeed, it appears to me that there may be an effect of the drug in p2rx7-deficient animals, even if the difference didn\'t reach a similar degree of statistical significance as in WT (perhaps due to the lower n?). Instead of reporting that there is no statistically significant effect of the drug in p2rx7 knockouts, I think it would be preferable to arrange the statistical testing in such a way that it is possible to conclude that the effect of the drug (fold restriction of bacterial burdens?) is statistically different in WT vs p2rx7 knockouts. In addition, is the Clemastine+P2RX7+ group significantly different than the Clemastine+P2RX7- group?

This point is well-taken. We have taken the reviewer's suggestion about this analysis in Figure 4---figure supplement 1B and 1C and Figure 6---figure supplement 1B. We felt it was important to show actual unprocessed data first (without the fold-change processing), so have left the analysis and comparisons in Figure 4A intact and still do note that there is no statistically significant effect of the drug in the *p2rx7* knockout. However, as the reviewer suggested, in Figure 4---figure supplement 1B, we now show that the fold-reduction in burden with clemastine is significantly lower in WT vs. *pr2rx7* knockouts (p=0.001). We also performed these same analyses on granuloma explants and observe similar effects (Figure 6---figure supplement 1B). In addition, in response to the reviewer's point 3 below, we performed 16S rRNA analysis on pooled larvae (four groups: WT vehicle, WT treated, p2rx7 vehicle, p2rx7 control) as a correlate of burden independent of fluorescence (Figure 4---figure supplement 1C) and found reduced burden in the WT animals and no effect in the p2rx7 knockouts.

Additionally, we have performed similar analyses for data supporting our findings in RD1 mutant bacteria and *asc* mutant animals. These new figures can be found in Figure 5---figure supplement 1C and Figure 5---figure supplement 2C. We show that clemastine reduces the fold change in bacterial burden compared to vehicle controls in wildtype infections more than RD1 mutant infections (Figure 5---figure supplement 1C). These data are also corroborated with 16S rRNA qPCR analysis within the same figure. Finally, we use this reviewer's suggestion for additional analysis based on fold change to confirm that clemastine reduces the fold change in bacterial burden in wildtype animals compared to *asc* mutants (Figure 5---figure supplement 2C). Thus, not only is there a lack of a significant clemastine effect on infections with RD1 bacterial mutants, *asc* mutants, or *p2rx7* mutants, as shown previously, but the additional analysis suggested by the reviewer also reveals a statistically significant difference in the fold restriction of bacterial burden by clemastine between WT animals and each of these three genotypes. We hope these additional analyses, new experiments, and independent approaches to quantitate burden address this major concern.

> Reviewer \#4:
>
> \[...\] Essential revisions:
>
> 1\) RD1 data and link to the inflammasome: The authors show that clemastine does not further restrict the growth of an RD1 mutant, which lacks ESX-1 and thus fails to permeabilize the phagosome. This is interpreted as demonstrating that the drug only has efficacy if the bacterium has access to cytosolic contents, which is then used to justify thinking about how the inflammasome might be involved. I think this is problematic on two fronts: (1) An attenuated mutant (the RD1 mutant) might not be further growth-restricted by a host-directed drug for many reasons other than cytosolic access. I think (at minimum) testing the effect of clemastine against an attenuated mutant still able to access the cytosol would be necessary to begin to make that interpretation (2) The logical bridge between the requirement for cytosolic access and inflammasome activation is a weak one. The literature is divided on whether ESX-1 (i.e. cytosolic access of the bacterium) is required for activation of the two inflammasomes shown to be relevant in TB- AIM2 and NLRP3. While older literature suggested that activation of NLRP3 required ESX-1, the paper (PMID: 26048138) that best dissected out the relative contributions of NLRP3 and AIM2 to the overall inflammasome response to TB found that while ESX-1 was required for AIM2 activation, it was not required for NLRP3 activation. Further, permeabilizing the phagosome is known to be required for triggering other pathways, among other effects- to me, even though the ASC mutant data shows clemastine has no effect, there are logical gaps in getting to that experiment. I think the paper would be logically stronger if the RD1 and inflammasome data were removed.

While the RD1 data and ASC data are robust, we agree that this is a complex part of the field that may be difficult to fully resolve within the time-frame and scope of a revision. To strengthen this aspect of the manuscript, we have performed new experiments that (1) address the specificity of the RD1 effect and (2) provide some evidence (beyond genetic dependence on *asc*) of clemastine-treated granulomas exhibiting increased inflammasome-associated activity.

To address the reviewer's first concern, we tested the effect of clemastine against other mycobacterial mutants. Many of the attenuated mutants we tried (e.g. *erp*) were so attenuated that they were not useful in these assays, as they were being cleared on their own. However, we found that a bacterial mutant with a transposon insertion in *cmaA2* was attenuated in our model. CmaA2 encodes a mycolic acid trans-cyclopropane synthetase (Glickman et al., 2001). While we did not seek to define the mechanism for *cmaA2* mutant attenuation in our model, we show that these bacteria fail to expand normally in vivo. Despite their attenuation and low bacterial burden, clemastine treatment further reduces bacterial burden by \~0.5 log~10~ in *cmaA2* mutants (Figure 5---figure supplement 1B-C), in contrast to the RD1 results. In addition, we used a reciprocal approach in which we infected with a high dose of RD1 mutant bacteria to show that even with a higher burden of infection, clemastine remains ineffective against RD1 mutant bacteria (Figure 5---figure supplement 1B-C), described in subsection "Clemastine is effective in established infections".

We agree that the literature is complex and sometimes contradictory on how, whether, and when ESX-1 and/or cytosolic access is required for activation of inflammasomes during mycobacterial infection. The finding that clemastine was ineffective against RD1 mutant bacteria led us to investigate the inflammasome as a mechanism through which clemastine can reduce bacterial burden, as we know that ESX-1 secretion systems have been implicated in both the activation and inhibition of inflammasomes during mycobacterial infection. The manuscript does not seek to resolve the role of RD1/ESX1 in inflammasome activation. Rather, it was the impetus to examine this pathway and the *asc* mutants and find that clemastine was ineffective in both *p2rx7* and *asc* mutants. We also have added Figure 6C and Figure 6---figure supplement 2A-C, in which we devised a protocol for quantitating FLICA-reagent fluorescence in granuloma explants after clemastine treatment, suggesting increased inflammasome activity after clemastine treatment. Unfortunately, the administration and/or sensitivity of this reagent did not allow us to perform these experiments in larvae.

To bolster the case for specificity, we also added negative data investigating a potential role for autophagy in mediating clemastine's effects. In new Figure 5---figure supplement 2D, we see no difference in LC3 positive puncta upon clemastine treatment using a previously published zebrafish line (He et al., 2009).

> 2\) Lack of testing in combination with an established anti-mycobacterial drug: Host acting agents have relatively weak activity against Mtb when compared with standard antibiotics and will likely have to be used as adjuncts to other therapeutics. In some cases, drugs with activity against Mtb in host cells when used alone have been shown to compromise the activity of standard antibacterial agents when used in combination. An argument can be made that the standard for testing potential novel host-directed agents should include testing together with more standard antibiotics. If this type of model is not already established in the lab, these experiments would potentially go beyond 60 days- in which case I would still support publication of the manuscript without those experiments but would suggest that the potential for different effects in combination/need to test in combinations be addressed in the Discussion section.

We wholeheartedly agree that host-acting agents typically have weak activity against *Mtb* when compared to standard of care antibiotics. HDTs would be used in conjunction with the standard of care in any human trial or treatment. While the time-frame of the revision precluded a comprehensive examination of front-line antibiotics, we examined the effects of clemastine in conjunction with the antibiotic moxifloxacin, selected in part because it displayed reduced efficacy in the granuloma model (10-fold higher MIC relative to in vitro MIC -- Cronan et al., 2018). In combination with moxifloxacin, clemastine co-treatment is more effective than antibiotic alone (Figure 6F and Figure 6---figure supplement 3C and subsection "Transgenic lines").

\[Editors' note: the author responses to the re-review follow.\]

We would like the thank the reviewers for their thorough and thoughtful critique of our manuscript. We are pleased to have had the opportunity to present the information more clearly and perform new experiments to address reviewer concerns. We have added substantial new experimental data, including validating findings about bacterial burden with three additional independent approaches and find even more robust effects in the established granuloma model (now using three independent approaches to quantify burden) than we had presented previously in the larval infection model. We have addressed statistical concerns more comprehensively throughout, and strengthened the findings around RD1 and inflammasome activation using new mycobacterial mutants, additional experiments, and a flow-cytometry-based analysis of clemastine's effect on established granulomas. In addition, as requested by the reviewers, we have shown efficacy of clemastine in combination with a traditional antibiotic. And we have reworded significant aspects of the discussion to make clear the novel biological findings and approach within the context of the zebrafish-mycobacterial infection system, a natural host-pathogen pairing. In summary, we hope we have addressed the reviewers' concerns through a number of additional experiments, thoughtful rewording, and careful statistical analysis throughout.

As presented below in more detail, we have addressed each of these points with new experiments.

Regarding the effect size of clemastine initially reported (\~0.5-1.0 log~10~ by fluorescence), within our model -- a slow growing mycobacterium over the five-day infection possible in the zebrafish larva -- this represents a fairly large and robust effect size. It is on a par with effect sizes described for host perturbations in a number of other zebrafish-mycobacterium papers over the past 15 years (e.g. Clay et al., 2007; Tobin et al., 2010; Tobin et al., 2012; Roca and Ramakrishnan, 2013; Oehlers et al., 2015 among others). Many of these findings have been validated in other mycobacterial infection models and in human populations. In addition, we performed new experiments to validate the robustness of the effect.

Importantly, the development of a new granuloma explant model has allowed us to examine treatment over longer time-frames with established infections as well as enabled new approaches to quantifying burden (thereby independently validating the fluorescence-based results) that are not possible in the larvae. In new experiments, we found that clemastine's effect on burden measured by CFU was a 27-fold (1.4 log~10~) median reduction over seven days of treatment in established infections. We also developed a new lux-based strain for longitudinal quantitation in established granulomas and obtained similar results.

In the revised manuscript, we have further clarified all statistical tests. All significant p-values are presented within the figure and all non-significant p-values are described in each figure legend. Additionally, all p-values (for both transformed and untransformed data) are presented in Supplementary file 2 and Supplementary file 3. New experiments are included to correlate fluorescent readouts with CFU, 16S bacterial rRNA, and a new mycobacterial strain that expresses Lux to provide an even more accurate and independent readout of bacterial counts within nascent and established infections. Using the granuloma explant model and flow cytometry, we have further expanded our investigation of the role for clemastine in activation of the inflammasome; clemastine treatment efficacy is not only dependent on *asc* but, in new data, we detect enhanced activation of caspase-1 via a FLICA reagent and flow cytometry of established granulomas treated with clemastine.

> 1\) In the absence of rigorous statistical analysis, or the lack of a clear explanation as to how statistics were conducted, small (or even large) changes in a biological system are difficult to contextualize. We encourage you to consider this carefully in your data analysis. Regards statistics, pay particular attention to the correct choice of test to use, usually determined by the nature of the data, parametric versus non-parametric etc. Report these consistently in all figures, provide p-values for all comparisons (include the choice of test each time) and if necessary, include an expanded data analysis section in the Materials and methods section.

We have more clearly explained how we conducted our statistical analyses and included much more information about the analyses we did perform. We have reported all p values for both transformed and untransformed data as requested by one of the reviewers and this is now included comprehensively in new Supplementary file 2 and Supplementary file 3.

> 2\) Consider more carefully how you would incorporate inflammasome activation as the mechanism into your revision. Reviewers raised several concerns regards the RD1 mutant. However, simply removing it from the study may weaken the mechanism. We encourage you to think further as to how you can address this concern.

To further address these concerns, and as detailed below and above, we performed additional experiments that were supportive of this model. These included generating and assessing a new mycobacterial mutant to rule out the possibility of burden-dependent efficacy of clemastine; calibrating RD1 infection levels to address this same issue; and developing a new protocol in established granulomas to quantitate caspase-1 activation via a FLICA reagent upon clemastine treatment. More details are provided in the point-by-point response to reviewers.

> 3\) We would like to affirm your sentiment that eLife values model systems as central to the scholastic pursuit of holistically understanding biological systems. The zebrafish model is no different in this case. However, it falls upon the authors to ensure that data presented in any manuscript are interpreted within the context of said model and not over-extended to humans or any other system without substantiating experiments. Please consider this carefully when preparing your revision and limit the interpretation to the model system that you are using, unless you have supporting/validation data from other systems.

We appreciate that our findings come within the context of an animal model of mycobacterial infection and have emphasized the new biological insights obtained using a natural host-pathogen pairing and an in vivo drug screen. We have restructured the Introduction and Discussion section to focus on those findings within this context, and while we do believe that animal models of mycobacterial infection are useful in understanding conserved fundamental features of mycobacterial infection, have been careful to emphasize that our findings are within this particular system.
